FALL INTO FUN and FIRST CLASS EDUCATION

MEETING PROGRAM 2012

64TH ANNUAL MEETING OF THE NORTHEASTERN SECTION AUA
Welcome to Niagara Falls and the 64th Annual Meeting of the Northeastern Section of the American Urological Association.

With the two hundred year anniversary of the War of 1812 being recognized this year it seems only fitting that our meeting is being held in the Niagara region, an area that played a prominent and strategic role in the battle between the young nation of the United States of America and British North American forces. The outcome of the war had a significant impact on the maturation of America but also on the development of a new nation, Canada. The treaties and boundaries created from the armistice laid the groundwork for a strong and healthy relationship that continues to this day and is a source of pride to the citizens of both our nations.

Dr. Stephen Pautler, the Scientific Program Chair has assembled an outstanding educational program that will be of interest to residents, community and academic urologists. The program has been devised to promote audience participation with the inclusion of a number of panel discussions. Within our Section we are blessed to have an enormous array of urological talent with many established as well as up and coming academic leaders. Dr. Michael Jewett, a highly respected educator, thought-leader and pioneer will serve as this year’s Slotkin Lecturer. Dr. Mohit Bhandari, from McMaster University will give a thought provoking lecture on the revolution in evidence-based medicine and the impact on surgery. We are also fortunate to have secured a number of world renowned faculty from outside the section. Dr. Paul Russo from Memorial Sloan Kettering will provide a state-of-the-art review of advanced kidney cancer care. Dr. Ann Gormley will provide an update on the management of female urinary incontinence. Dr. Tony Khoury, a former member of our section and now the Chief of Pediatric Urology at the University of California at Irvine will speak and lead a panel discussion on pediatric urology challenges. Dr. Li-Ming Su will present a futuristic vision of minimally invasive surgery. Dr. Bodo Knudsen currently at Ohio State and a former resident from our section will speak on recent advances in percutaneous renal surgery and ureteroscopy. A distinguished panel headed by Dr. Brent Hollenbeck will address surgical quality assurance as it relates to prostate cancer surgery. Resident involvement in the program will again include the popular resident debates as well as “Urology Reach for the Top” and a laparoscopic skills competition in the Exhibit Hall.

September in the Niagara region is a delightful time and the social program will highlight the area’s natural beauty. The back drop for Fun Night will be the majestic Niagara Falls. Food and wine lovers will enjoy the many local restaurants and wineries and the world famous Shaw Festival will delight theatre-goers. The region is a golfer’s haven and we are fortunate to have secured the Thundering Waters Golf Club for the Section’s golf tournament on Saturday.

I look forward to seeing you during our time here in Niagara Falls!

Hassan Razvi, MD
DISTINGUISHED FACULTY

GEORGE E. SLOTKIN LECTURER

MICHAELA.S. JEWETT
Professor of Surgery, Division of Urology
University of Toronto
Toronto, ON

MOHIT BHANDARI
McMaster University
Hamilton, ON

E. ANN GORMLEY
Dartmouth-Hitchcock Medical Center
Lebanon, NH

BRENT K. HOLLENBECK
University of Michigan
Ann Arbor, MI

ANTOINE E. KHOURY
University of California, Irvine
Irvine, CA

BODO E. KNUDSEN
Ohio State University
Columbus, OH

CHERYL T. LEE
University of Michigan
Ann Arbor, MI

PAUL RUSSO
Memorial Sloan Kettering Cancer Institute
New York, NY

LI-MING SU
University of Florida
Gainesville, FL
**Schedule-At-A-Glance**

**THURSDAY, SEPTEMBER 13, 2012**
- Plenary Lectures, Physician Panels & Resident Debates: Incontinence; Kidney Cancer; Endourology; Pediatrics
- Moderated Poster Sessions
- Industry Sponsored Symposia*
- Resident Laparoscopic Skills Competition
- Spouse Tour: Shaw Festival
- Exhibit Hall Grand Opening Reception

**FRIDAY, SEPTEMBER 14, 2012**
- 5K Fun Run/Walk
- Plenary Lectures, Physician Panels & Resident Debates: Evidence Based Medicine; Surgical Quality Assurance; Genitourinary Reconstruction
- George E. Slotkin Lecture – The Evolution of Testis Cancer
- Industry Sponsored Symposia*
- Resident Laparoscopic Skills Competition
- Moderated Poster Sessions
- Young Urologist Mentoring Program
- Spouse Tour: Niagara Highlights
- Fun Night at Table Rock Centre

**SATURDAY, SEPTEMBER 15, 2012**
- Residents Breakfast
- Plenary Lectures and Physician Panel: Robotics; Laparoscopy Video
- AUA Course of Choice – Management of Non Muscle Invasive Bladder Cancer
- Resident Reach for the Top Competition
- Golf Tournament
- Volunteer Opportunity – Red Roof Retreat
- Tour Option – Art of the Blend
- President’s Reception & Banquet

*Industry sponsored symposia are separate from the Section’s designated CME scientific program.

**REGISTRATION HOURS**
- Wednesday: 5:00 – 7:00 p.m.
- Thursday: 6:30 a.m. – 5:00 p.m.
- Friday: 7:00 a.m. – 5:00 p.m.
- Saturday: 7:00 a.m. – Noon

**EXHIBIT HALL HOURS**
- Thursday: 12:30 – 3:30 p.m.
- 6:00 – 7:00 p.m.
- Friday: 9:30 a.m. – 1:30 p.m.

**SPEAKER READY ROOM – ROOM 205**
- Wednesday: 5:00 – 7:00 p.m.
- Thursday: 7:00 a.m. – 6:00 p.m.
- Friday: 7:00 a.m. – 6:00 p.m.
- Saturday: 7:00 a.m. – Noon
# Schedule-At-A-Glance

**THURSDAY, SEPTEMBER 13, 2012**

<table>
<thead>
<tr>
<th>Time</th>
<th>Peller Estates Ballroom A</th>
<th>Peller Estates Ballroom B</th>
<th>Room 201/202</th>
<th>Room 207/208</th>
<th>Peller Estates Ballroom CD</th>
</tr>
</thead>
<tbody>
<tr>
<td>8 a.m.</td>
<td><strong>7:30 - 7:45 a.m. Opening Session</strong></td>
<td><strong>6:30 - 7:30 a.m. Industry Breakfast Symposium</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>7:45 - 8:30 a.m. Plenary I</strong></td>
<td><strong>Management of the Incontinent Woman</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>8:30 - 8:45 a.m. Resident Debate</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9 a.m.</td>
<td><strong>8:45 - 9:15 a.m. Plenary II</strong></td>
<td><strong>Aggressive Kidney Cancer - What to do?</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>9:15 - 9:45 a.m. Panel: What To Do with a Small Renal Mass?</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10 a.m.</td>
<td></td>
<td><strong>9:45 - 10:15 a.m. Break</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>10:15 - 10:45 a.m. Plenary III</strong></td>
<td><strong>ESWL: Is it dead?</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>10:45 -11:30 a.m. Panel: Difficult Cases in Endourology</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12 p.m.</td>
<td></td>
<td>11:30 a.m.-12:30 p.m. Industry Lunch Symposium</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 p.m.</td>
<td><strong>12:30 - 1:30 p.m. Exhibit Hall Sneak Peek Opening</strong></td>
<td><strong>Resident Lap Skills Competition</strong></td>
<td></td>
<td></td>
<td><strong>12:30 - 3:30 p.m. Exhibit Hall Open</strong></td>
</tr>
<tr>
<td>2 p.m.</td>
<td><strong>1:30 - 2:00 p.m. Plenary IV</strong></td>
<td><strong>Advances in Pediatrics</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>2:00 - 2:30 p.m. Panel: Controversies in Pediatrics</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>2:30 - 2:45 p.m. Resident Debate</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3 p.m.</td>
<td><strong>2:45 - 3:15 p.m. Break in Exhibit Hall</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4 p.m.</td>
<td></td>
<td><strong>3:15 - 5:00 p.m. Moderated Poster Session I Oncology 1</strong></td>
<td><strong>3:15 - 5:00 p.m. Moderated Poster Session II Lapi/Robotics; Stones/Endo: Education</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5 p.m.</td>
<td></td>
<td><strong>5:00 - 6:00 p.m. Industry Reception Symposium</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6 p.m.</td>
<td></td>
<td><strong>6:00 - 7:00 p.m. Exhibit Hall Grand Opening Reception</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
# Schedule-At-A-Glance

## FRIDAY, SEPTEMBER 14, 2012

<table>
<thead>
<tr>
<th>Time</th>
<th>Peller Estates Ballroom A</th>
<th>Peller Estates Ballroom B</th>
<th>Room 201/202</th>
<th>Room 207/208</th>
<th>Peller Estates Ballroom CD</th>
<th>Hotel</th>
</tr>
</thead>
<tbody>
<tr>
<td>7 a.m.</td>
<td>6:30 - 7:30 a.m. Industry Breakfast Symposium</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| 8 a.m.| 7:30 - 7:45 a.m. Best-of-Posters  
8:15 - 9:00 a.m. Plenary V  
The Evidence Based Medicine Revolution: A Surgeon’s Perspective |
| 9 a.m.| 7:45 - 8:15 a.m. Section Stars  
Prize Winning Essays  
Young Investigator  
Plenary VI  
Improving the Quality of Care Among Men With Prostate Cancer  
Panel: Surgical Quality Assurance |
| 10 a.m.| 9:00 - 9:45 a.m. Plenary VI  
Improving the Quality of Care Among Men With Prostate Cancer Panel: Surgical Quality Assurance  
10:15 a.m. - Noon  
Moderated Poster Session III  
Oncology II |
| 11 a.m.| 10:15 a.m. - Noon  
Moderated Poster Session IV  
Trauma; Voiding; Renal; Infertility; General |
| 12 p.m.| Noon - 1:30 p.m. Lunch in Exhibit Hall  
Resident Lap Skills Competition – Finals |
| 1 p.m.| 1:30 - 2:15 p.m.  
George E. Slotkin Lecture  
The Evolution of Testis Cancer Care  
2:15 - 2:45 p.m.  
Panel: Genitourinary Reconstruction |
| 2 p.m.| 2:45 - 3:00 p.m. Break  
3:00 - 4:30 p.m.  
Moderated Poster Session V  
Basic Science  
3:00 - 3:45 p.m.  
Moderated Poster Session VI  
Pediatrics |
| 3 p.m.| 4:30 - 6:00 p.m.  
Young Urologist Mentoring Program (Salon A)  
5:30 - 6:30 p.m.  
Residents Reception |
| 4 p.m.|  |
| 5 p.m.|  |
| 6 p.m.|  |
# Schedule-At-A-Glance

**SATURDAY, SEPTEMBER 15, 2012**

<table>
<thead>
<tr>
<th>Time</th>
<th>Peller Estates Ballroom A</th>
<th>Hotel</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:30 - 8:30 a.m.</td>
<td>Business Meeting</td>
<td>7:30 - 8:30 a.m. Residents Breakfast (Niagara Room)</td>
</tr>
<tr>
<td>8 a.m.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:30 - 8:45 a.m.</td>
<td>Best-of-Posters</td>
<td></td>
</tr>
<tr>
<td>8:45 - 9:00 a.m.</td>
<td>AUA Guidelines Panel Update</td>
<td></td>
</tr>
<tr>
<td>9:00 - 9:45 a.m.</td>
<td>Plenary VI Image-guided Robotic Urologic Surgery</td>
<td></td>
</tr>
<tr>
<td>9:45 - 10:00 a.m.</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>10 a.m.</td>
<td>10:00 - 10:45 a.m. Panel: Laparoscopy Video - How I do it…</td>
<td></td>
</tr>
<tr>
<td>10:45 - 11:30 a.m.</td>
<td>AUA Course of Choice Management of Non Muscle Invasive Bladder Cancer</td>
<td></td>
</tr>
<tr>
<td>11 a.m.</td>
<td>11:30 a.m.-12:15 p.m. Resident Reach for the Top Competition</td>
<td></td>
</tr>
<tr>
<td>12 p.m.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>6:30 - 10:00 p.m.</td>
<td>President’s Reception and Dinner (Hennepin Ballroom)</td>
<td></td>
</tr>
</tbody>
</table>
# Board and Committee Listings

## NORTHEASTERN SECTION BOARD OF DIRECTORS

<table>
<thead>
<tr>
<th>Position</th>
<th>Name</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PRESIDENT</strong></td>
<td>Hassan Razvi, MD</td>
<td>London, Ontario</td>
</tr>
<tr>
<td><strong>PRESIDENT-ELECT</strong></td>
<td>Zahi N. Makhuli, MD</td>
<td>Syracuse, New York</td>
</tr>
<tr>
<td><strong>IMMEDIATE PAST PRESIDENT</strong></td>
<td>Edward M. Messing, MD</td>
<td>Rochester, New York</td>
</tr>
<tr>
<td><strong>SECRETARY</strong></td>
<td>Ronald P. Kaufman Jr., MD</td>
<td>Albany, New York</td>
</tr>
<tr>
<td><strong>TREASURER</strong></td>
<td>D. Robert Siemens, MD</td>
<td>Kingston, Ontario</td>
</tr>
<tr>
<td><strong>HISTORIAN</strong></td>
<td>Ronald Rabinowitz, MD</td>
<td>Rochester, New York</td>
</tr>
<tr>
<td><strong>AUA BOARD REPRESENTATIVE</strong></td>
<td>Kevin Pranikoff, MD</td>
<td>Eggerts ville, New York</td>
</tr>
<tr>
<td><strong>REPRESENTATIVES</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>CANADA</strong></td>
<td>Karen J. Psooy, MD</td>
<td>Winnipeg, Manitoba</td>
</tr>
<tr>
<td><strong>NEW YORK</strong></td>
<td>Elise J. Billings De, MD</td>
<td>Albany, New York</td>
</tr>
<tr>
<td><strong>PENNSYLVANIA</strong></td>
<td>Timothy D. Averch, MD</td>
<td>Pittsburgh, Pennsylvania</td>
</tr>
<tr>
<td><strong>AT-LARGE CANADA</strong></td>
<td>Kenneth T. Pace, MD</td>
<td>Toronto, Ontario</td>
</tr>
<tr>
<td><strong>AT-LARGE UNITED STATES</strong></td>
<td>Badar M. Mian, MD</td>
<td>Albany, New York</td>
</tr>
<tr>
<td><strong>YOUNG UROLOGIST MEMBERS</strong></td>
<td>Julie Franc-Guimond, MD</td>
<td>Montreal, Quebec</td>
</tr>
<tr>
<td></td>
<td>Michael Ost, MD</td>
<td>Pittsburgh, Pennsylvania</td>
</tr>
<tr>
<td><strong>EXECUTIVE DIRECTOR</strong></td>
<td>Drew N. Shifflet, CAE</td>
<td></td>
</tr>
</tbody>
</table>

## 2011–2012 NS-AUA COMMITTEES

<table>
<thead>
<tr>
<th>Committee</th>
<th>Chair</th>
<th>Members</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>BYLAWS</strong></td>
<td>Ronald P. Kaufman Jr., MD</td>
<td>Jean V. Joseph, MD, Alp Sener, MD</td>
</tr>
<tr>
<td><strong>DEVELOPMENT</strong></td>
<td>Joseph M. Greco, MD</td>
<td>David A. Corral, MD, Neil E. Fleschner, MD, Jerzy B. Gajewsky, MD, Pierre I. Karakiewicz, MD, David B. Patrick, MD</td>
</tr>
<tr>
<td><strong>INVESTMENT</strong></td>
<td>D. Robert Siemens, MD</td>
<td>D. Robert Siemens, MD, Jerzy B. Gajewsky, MD, Hassan Razvi, MD, Mark D. White, MD</td>
</tr>
<tr>
<td><strong>HEALTH POLICY</strong></td>
<td>Ronald P. Kaufman Jr., MD</td>
<td>Timothy D. Averch, MD, David P. Gentile, MD, Dharm R. Singh, MD</td>
</tr>
<tr>
<td><strong>NOMINATING</strong></td>
<td>Edward Messing, MD</td>
<td>Julie Franc-Guimond, MD, Anne-Marie Houle, MD, Anil Kapoor, MD, Joel B. Nelson, MD, Michael Ost, MD</td>
</tr>
<tr>
<td><strong>SCIENTIFIC PROGRAM</strong></td>
<td>Stephen E. Pautler, MD</td>
<td>Stephen E. Pautler, MD, Timothy D. Averch, MD, Anthony J. Bella, MD</td>
</tr>
<tr>
<td><strong>SCHOLARSHIP RESEARCH</strong></td>
<td>Jodi K. Maranchie, MD</td>
<td>Stephen E. Pautler, MD, Jehonathan H. Pinthus, MD, PhD, Guan Wu, MD, PhD</td>
</tr>
</tbody>
</table>

www.NSAUA.org
Thank You To Our Annual Meeting Supporters:

The Northeastern Section thanks the following companies for providing educational grants in support of the 2012 Annual Meeting as of 8/16/12:

- **ALLERGAN**
- **AMGEN**
- **eAMS**
- **endo**
- **Warner Chilcott**
- **Watson**

The Northeastern Section thanks the following companies for their general support of the 2012 Annual Meeting as of 8/16/12:

**PLATINUM SUPPORT**
- **FERRING PHARMACEUTICALS**

**GOLD SUPPORT**
- **AMGEN**
- **Dendreon**
  - Targeting Cancer, Transforming Lives™
- **Pfizer**

**SILVER SUPPORT**
- **Astellas**

**CONTRIBUTORS**
- **AstraZeneca**
- **OLYMPUS**
- **STORZ**
  - Karl Stora Lithotripsy
## Past Presidents/Meeting Locations

<table>
<thead>
<tr>
<th>YEAR</th>
<th>PRESIDENT</th>
<th>HOME CITY</th>
<th>MEETING SITE</th>
</tr>
</thead>
<tbody>
<tr>
<td>1948-1949</td>
<td>James C. McClelland*</td>
<td>Toronto ON</td>
<td>Bigwin Inn, Huntsville, ON</td>
</tr>
<tr>
<td>1949-1950</td>
<td>A. Lawrence Parlow*</td>
<td>Rochester, NY</td>
<td>The Sagamore, Lake George, NY</td>
</tr>
<tr>
<td>1950-1951</td>
<td>William J. Kennedy*</td>
<td>Gloversville, NY</td>
<td>Lake Placid Club, Lake Placid, NY</td>
</tr>
<tr>
<td>1951-1952</td>
<td>William A. Barrett*</td>
<td>Pittsburgh, PA</td>
<td>Hamilton Princess, Bermuda</td>
</tr>
<tr>
<td>1952-1953</td>
<td>David R. Mitchell*</td>
<td>Toronto, ON</td>
<td>Shawnee Inn, Shawnee on Delaware, PA</td>
</tr>
<tr>
<td>1953-1954</td>
<td>Albert M. Crance*</td>
<td>Geneva, NY</td>
<td>Chateau Frontenac, Quebec City, QC</td>
</tr>
<tr>
<td>1954-1955</td>
<td>Walter J. Hayward*</td>
<td>Jamestown, NY</td>
<td>Lake Placid Club, Lake Placid, NY</td>
</tr>
<tr>
<td>1955-1956</td>
<td>William Baurs*</td>
<td>Sayre, PA</td>
<td>Equinox House, Manchester, VT</td>
</tr>
<tr>
<td>1956-1957</td>
<td>Allan B. Hawthorne*</td>
<td>Montreal, QC</td>
<td>Whiteface Inn, Lake Placid, NY</td>
</tr>
<tr>
<td>1957-1958</td>
<td>William A. Milner*</td>
<td>Albany, NY</td>
<td>Equinox House, Manchester, VT</td>
</tr>
<tr>
<td>1958-1959</td>
<td>S. H. Johnson III*</td>
<td>Pittsburgh, PA</td>
<td>Seignory Club, Montebello, QC</td>
</tr>
<tr>
<td>1959-1960</td>
<td>Frances O. Harbach*</td>
<td>Syracuse, NY</td>
<td>Bedford Springs Resort, Harrisburg, PA</td>
</tr>
<tr>
<td>1960-1961</td>
<td>J. Victor Berry*</td>
<td>Ottawa, ON</td>
<td>Equinox House, Manchester, VT</td>
</tr>
<tr>
<td>1961-1962</td>
<td>John S. Fitzgerald*</td>
<td>Utica, NY</td>
<td>Grossinger’s, Liberty, NY</td>
</tr>
<tr>
<td>1962-1963</td>
<td>Hollister W. Lyon*</td>
<td>Punxsutawney, PA</td>
<td>Chateau Frontenac, Quebec City, QC</td>
</tr>
<tr>
<td>1963-1964</td>
<td>John A. Benjamin*</td>
<td>Rochester, NY</td>
<td>Pocono Manor, Pocono Manor, PA</td>
</tr>
<tr>
<td>1964-1965</td>
<td>Arthur Bedard*</td>
<td>Quebec City, QC</td>
<td>Otesaga Hotel, Cooperstown NY</td>
</tr>
<tr>
<td>1965-1966</td>
<td>Michael G. O’Brien*</td>
<td>Scranton, PA</td>
<td>Shawnee Inn, Shawnee on Delaware, PA</td>
</tr>
<tr>
<td>1967-1968</td>
<td>William E. Collins*</td>
<td>Ottawa, ON</td>
<td>Whiteface Inn, Lake Placid, NY</td>
</tr>
<tr>
<td>1968-1969</td>
<td>David W. Kline*</td>
<td>Greenville, PA</td>
<td>Whiteface Inn, Lake Placid, NY</td>
</tr>
<tr>
<td>1969-1970</td>
<td>Hobart L. Boyd*</td>
<td>Rochester, NY</td>
<td>Hershey Hotel, Hershey, PA</td>
</tr>
<tr>
<td>1970-1971</td>
<td>Charles L. Robson*</td>
<td>Toronto, ON</td>
<td>King’s Inn, Freeport, Grand Bahams</td>
</tr>
<tr>
<td>1971-1972</td>
<td>Charles C. Altman*</td>
<td>Pittsburgh, PA</td>
<td>Sheraton Hyannis, Cape Cod, MA</td>
</tr>
<tr>
<td>1972-1973</td>
<td>William J. Staebitz*</td>
<td>Buffalo, NY</td>
<td>Inn on the Park, Toronto, ON</td>
</tr>
<tr>
<td>1974-1975</td>
<td>Stuart E. Price*</td>
<td>Pittsburgh, PA</td>
<td>Buck Hill Inn, Buck Hill Falls, PA</td>
</tr>
<tr>
<td>1975-1976</td>
<td>Peter O. Crosswell*</td>
<td>Toronto, ON</td>
<td>The Homestead, Hot Springs, VA</td>
</tr>
<tr>
<td>1976-1977</td>
<td>Otto M. Lilien*</td>
<td>Syracuse, NY</td>
<td>Chateau Frontenac, Quebec City, QC</td>
</tr>
<tr>
<td>1977-1978</td>
<td>John F. Rose, Jr.</td>
<td>Danville, PA</td>
<td>Lake Placid Club, Lake Placid, NY</td>
</tr>
<tr>
<td>1978-1979</td>
<td>Andrew W. Bruce*</td>
<td>Kingston, ON</td>
<td>Hotel Bonaventure, Montreal, QC</td>
</tr>
<tr>
<td>1980-1981</td>
<td>Alan H. Irvine*</td>
<td>Ottawa, ON</td>
<td>Chateau Laurier Hotel, Ottawa, ON</td>
</tr>
<tr>
<td>1981-1982</td>
<td>Andre Vallieres*</td>
<td>Quebec City, QC</td>
<td>The Nevele Country Club, Ellenburg, NY</td>
</tr>
<tr>
<td>1982-1983</td>
<td>Leo M. King*</td>
<td>McKeensport, PA</td>
<td>Chateau Frontenac, Quebec City, QC</td>
</tr>
<tr>
<td>1984-1985</td>
<td>Martin Barkin*</td>
<td>Toronto, ON</td>
<td>The Copley Plaza Westin Hotel, Boston, MA</td>
</tr>
<tr>
<td>1985-1986</td>
<td>Pierre E. Bertrand</td>
<td>Quebec City, QC</td>
<td>The Four Seasons Hotel, Toronto, ON</td>
</tr>
<tr>
<td>1986-1987</td>
<td>David H. Barnhouse*</td>
<td>Pittsburgh, PA</td>
<td>The Breakers, Palm Beach, FL</td>
</tr>
<tr>
<td>1987-1988</td>
<td>Grant A. Farrow*</td>
<td>Toronto, ON</td>
<td>Hamilton Princess, Bermuda</td>
</tr>
<tr>
<td>1988-1989</td>
<td>Jack L. Sales*</td>
<td>London, ON</td>
<td>Chateau Champlain, Montreal, QC</td>
</tr>
<tr>
<td>1990-1991</td>
<td>Said A. Awad*</td>
<td>Halifax, NS</td>
<td>Colonial Williamsburg, VA</td>
</tr>
<tr>
<td>1992-1993</td>
<td>Normand Sullivan*</td>
<td>St. Anne de Sorel, QC</td>
<td>El San Juan Hotel, San Juan, PR</td>
</tr>
<tr>
<td>1993-1994</td>
<td>Anthony V. Passaretti*</td>
<td>Albany, NY</td>
<td>The Sagamore, Lake George, NY</td>
</tr>
<tr>
<td>1994-1995</td>
<td>Mostafa M. Elhilali*</td>
<td>Montreal, QC</td>
<td>Cairo Marriott Hotel, Cairo, Egypt</td>
</tr>
<tr>
<td>1996-1997</td>
<td>David B. Patrick*</td>
<td>Beaver, PA</td>
<td>Wigwam Resort, Phoenix, AZ</td>
</tr>
<tr>
<td>1997-1998</td>
<td>Alvaro Morales*</td>
<td>Kingston, ON</td>
<td>Royal York Hotel, Toronto, ON</td>
</tr>
<tr>
<td>1998-1999</td>
<td>David J. Albert*</td>
<td>Buffalo, NY</td>
<td>Southampton Princess, Bermuda</td>
</tr>
<tr>
<td>1999-2000</td>
<td>Kevin Prankhoff*</td>
<td>Buffalo, NY</td>
<td>The Westin Hotel, Pittsburgh, PA</td>
</tr>
<tr>
<td>2001-2002</td>
<td>Datta G. Wagle*</td>
<td>Williamsville, NY</td>
<td>Fairmont Mt. Tremblant, Mount Tremblant, QC</td>
</tr>
<tr>
<td>2003-2004</td>
<td>Mark F. Bellinger*</td>
<td>Pittsburgh, PA</td>
<td>Westin Hotel, Savannah, GA</td>
</tr>
<tr>
<td>2004-2005</td>
<td>John D. Denstedt*</td>
<td>London, ON</td>
<td>Southampton Princess, Bermuda</td>
</tr>
<tr>
<td>2005-2006</td>
<td>Gabriel P. Haas*</td>
<td>Syracuse, NY</td>
<td>Westin Hotel, Ottawa, ON</td>
</tr>
<tr>
<td>2007-2008</td>
<td>James W. L. Wilson*</td>
<td>Kingston, ON</td>
<td>Hyatt Tamaya, Santa Ana Pueblo, NM</td>
</tr>
<tr>
<td>2008-2009</td>
<td>Anne-Marie Houle*</td>
<td>Montreal, QC</td>
<td>Fairmont Queen Elizabeth, Montreal, QC</td>
</tr>
<tr>
<td>2009-2010</td>
<td>Joel B. Nelson*</td>
<td>Pittsburgh, PA</td>
<td>Westin Convention Center, Pittsburgh, PA</td>
</tr>
<tr>
<td>2010-2011</td>
<td>Edward M. Messing*</td>
<td>Rochester, NY</td>
<td>Roosevelt Hotel, New Orleans, LA</td>
</tr>
</tbody>
</table>

* Deceased
Dr. George E. Slotkin

EXCERPT FROM THE WATERWAYS CHAPTER:

“No history of the Northeastern Section is complete without a short biography of this indefatigable urologist. Dr. George E. Slotkin (1890-1971) was born in New York City but soon moved with his parents to Buffalo, NY, where he spent his professional career. We acknowledge him today as a founder, the first benefactor, and the first historian of the NS, but there is more to his story.

If one were to hold up a mirror to the changing face of urology in the first half of the 20th century, it would be well reflected with an image of George E. Slotkin. A graduate of the University of Buffalo Medical School, Dr. Slotkin did postgraduate work at the New York City Post Graduate Hospital, the University of Vienna, and the University of Budapest. In 1918, he became a clinical professor of urology at the University of Buffalo. During the late 1940s, his clinical interest was tuberculosis of the urinary tract, which he treated with chalazomoric acid. Even though results of his work in this area remain inconclusive, other fruits of his career do not. Friends and colleagues of his time were fond of saying, ‘George Slotkin has three loves: urology, his wife Helene, and his Rolls Royce...not necessarily in that order!’ His early work, ‘Nephroptosis, a resurrected disease,’ was published in The Urologic and Cutaneous Review in 1938. His later work with E.A. Mercer, ‘Case of epispidias with a double urethra,’ was published in The Journal of Urology in 1953.

Obviously, this change in his work reflects the change in urology from its early focus on genitourinary disease to its present focus as a surgical specialty. Dr. Slotkin was named Clinical Professor of Urology Emeritus in 1954 by the University of Buffalo Medical School and continued his private practice until 1964. After retirement, he continued to write, contributing a fascinating chapter about the history of the Northeastern Section to History of Urology. It is a priceless, logical record of carefully researched facts.

His obituary notice implies that he may have been the first American invited to join the Canadian Urological Association. Dr. and Mrs. Slotkin did not have any children; his estate included a generous bequest to the Northeastern Section to provide funding for invited guest speakers at our annual meetings.”


GEORGE E. SLOTKIN LECTURERS

1975  Prof. Willie L. M. Gregoir, Brussels, Belgium
1976  J. Engelbert Dunphy, MD, San Francisco, California
1977  B. E. Christopher Nordin, MD, Leeds, England
1978  Donald Smith, MD, Piscataway, New Jersey
1979  J. Genest, MD, Montreal, Quebec
1980  Joseph J. Kaufman, MD, Los Angeles, California
1982  Donald S. Coffey, MD, Baltimore, Maryland
1983  Martin I. Resnick, MD, Cleveland, Ohio
1984  Willet F. Whitmore, Jr., MD, New York, New York
1985  Peter Scardino, MD, Houston, Texas
1986  William Fair, MD, New York, New York
1987  John Duckett, MD, Philadelphia, Pennsylvania
1989  Robert Jeffs, MD, Baltimore, Maryland
1990  Charles J. Devine, MD, Norfolk, Virginia
1991  Thomas Stamey, MD, Stanford, California
1992  Michael E. Mitchell, MD, Seattle, Washington
1993  Donald S. Coffey, MD, Baltimore, Maryland
1994  Carl Olsson, MD, Larchmont, New York
1995  Peter Scardino, MD, Houston, Texas
1996  Bernard M. Churchill, MD, Los Angeles, California
1997  Peter R. Carroll, MD, San Francisco, California
1998  Joyce Lisa Tenover, MD, Atlanta, Georgia
1999  Richard D. Williams, MD, Iowa City, Iowa
2000  Gerry G. Blaivas, MD, New York, New York
2001  Alvaro Morales, MD, Kingston, Ontario
2002  Edson Pontes, MD, Detroit, Michigan
2003  Gerald L. Andriole, MD, St. Louis, Missouri
2004  Mustafa Elhilali, MD, Montreal, Quebec
2005  Margaret Sue Pearle, MD, Dallas, Texas
2006  Mani Menon, MD, Detroit, Michigan
2007  Darius Jehan Bagli, MD, Toronto, Ontario
2008  S. Larry Goldenberg, MD, Vancouver, British Columbia
2009  Philip G. Ransley, MD, London, United Kingdom
2010  Joseph A. Smith, MD, Nashville, Tennessee
2011  Jean B. deKernion, MD, Los Angeles, California
2012  Michael A.S. Jewett, MD Toronto, Ontario
MOHIT BHANDARI, MD
Dr. Mohit Bhandari is a Professor and Academic Head of the Division of Orthopaedic Surgery at McMaster University in Hamilton Ontario. Dr. Bhandari holds a Canada Research Chair in Musculoskeletal Trauma and Surgical Outcomes. Dr. Bhandari has spent over a decade conducting internationally recognized research and several critical clinical trials in improving the lives of individuals with musculoskeletal injuries, as well as understanding the surgeon’s role in creating awareness and support for victims of intimate partner violence (IPV). His research interests include large clinical trials, intimate partner violence in a trauma setting, global health, and road traffic safety.

E-ANN GORMLEY, MD
Dr. E-Ann Gormley, is currently Professor of Surgery (Urology) and the program director of the Urology Residency at Dartmouth-Hitchcock Medical Center in Lebanon, New Hampshire. Dr. Gormley received a BA in English and her medical degree at the University of Saskatchewan. While completing her residency in Urology at the University of Alberta she earned an MSc in Experimental Surgery. She then completed a fellowship in Female Urology with Dr. E.J. McGuire at the University of Michigan and the University of Texas.

Active in the AUA, Dr. Gormley is the secretary for the New England Section of the AUA and sits on the Section Secretaries Committee and the AUA By-laws Committee. Dr. Gormley served as a member of the AUA/ABU Exam Committee from 2003-2006. Since 2009 she has been the Editor of the Exam Committee. She currently is a member of the Core Curriculum Committee and a member of the Medical Students Committee. Dr. Gormley served on the AUA Stress Incontinence Guidelines and recently chaired the AUA Overactive Guidelines Panel.

Dr. Gormley’s interests are in female urology, voiding dysfunction and resident education. She is the Chairman of the Steering Committee for the NIDDK’S Urinary Incontinence Network and a Past President of the Society for Urodynamics and Female Urology (SUFU). Dr. Gormley is the President of the Society of Urology Chairmen and Program Directors (SUCPD). She has served as a board examiner for the American Board of Urology since 2009. She is a peer reviewer for the Journal of Urology, Neurourology and Urodynamics, International Urogynecology and the Journal of Pelvic Surgery.

BRENT K. HOLLENBECK, MD, MS
Dr. Brent K. Hollenbeck is an Associate Professor of Urology and the Director of the Herbert H. and Grace A. Dow Division of Health Services Research at the University of Michigan. Dr. Hollenbeck completed his residency in urology and fellowship training in oncology at the University of Michigan. Dr. Hollenbeck also received a Masters of Science program in research design and biostatistics at the University of Michigan’s School of Public Health. His research interests are policy-oriented and focused squarely on understanding the upstream influences and downstream consequences of variation in physician practice style. His current initiatives include measuring the effects of physician financial incentives and identifying better practices for early stage bladder cancer. The former consists of an R01 from the Agency for Healthcare Research and Quality to better understand relationships between ambulatory surgery centers and outpatient surgery use. The latter is funded by the American Cancer Society and uses alternative statistical methods (e.g., instrumental variables analysis) to make inferences from observational data.

MICHAEL A. S. JEWETT, MD
Dr. Michael Jewett is a UroOncologist at the Princess Margaret Hospital of the University Health Network in Toronto, Canada and a Professor of Surgery in the Division of Urology at the University of Toronto. Dr. Jewett was the Chairman of the Division of Urology at the University of Toronto and Head of Urology at the University Health Network, which incorporates the Princess Margaret Hospital. He is a recent Past-President of the Canadian Urology Association. He holds two academic Chairs, the most recent by national competition, the Farquharson Clinical Research Chair in Oncology.

He is a past President of the Canadian Urology Association and received the Canadian Urological Association Award in 2011. He was elected an Honorary Member of the American Urological Association and received the Distinguished Contribution Award in 2011. He received the Society of Urological Oncology Medal in 2011. He is a Fellow of the American Association of Genitourinary Surgeons.

He has been a visiting professor to more than 100 universities and associations. He has more than 300 peer reviewed publications and book chapters.

He is a founding member of the Toronto Testis Tumour Group, co-chair of the recent Canadian Testis Cancer Consensus Meeting and a member of the recent European Society of Medical Oncology and International Consensus groups. He was the first to describe the nerve sparing technique of RPLND which is now the world standard for retroperitoneal lymph node dissection. He has extensive experience with this technique. He and his group have been world leaders in surveillance for early stage disease. For many years, he taught the annual postgraduate course on testis cancer at the Annual Meeting of the American Urological Association. He has published extensively in this field as well as in other UroOncology subjects, particularly kidney cancer.

ANTOINE E. KHOURY, MD
With over 25 years of experience, Dr. Khoury is the head of Pediatric Urology at the Children’s Hospital of Orange County and Walter R. Schmid Professor of Pediatric Urology and Professor in the Department of Urology at the University of California, Irvine.
2012 Faculty

Dr. Khoury completed his residency training at the University of Toronto and did his fellowship training in Pediatric Urology at the Hospital for Sick Children in Toronto. Dr. Khoury has also spent time at the University of Calgary carrying out research in infection and biomaterials. His work there resulted in several publications and a patent award on the bioelectric mechanism to eliminate bacterial biofilms. He joined the faculty of the Division of Urology at the Hospital for Sick Children in Toronto and was the Division Head from 1995 – 2008 before moving to Southern California.

His special interests are in reconstructive surgery of the genitourinary tract, urological malignancies and complex hypospadias repairs. He has maintained an active laboratory research effort and has established extensive collaborations, nationally and internationally in the fields of infection, biomaterials and regenerative medicine. He is currently developing a program for transition of care for Spina Bifida patients into adulthood.

Dr. Khoury’s CV includes more than 200 publications, 33 book chapters, 250 presentations at national and international meetings and he has delivered over 160 lectures as a visiting professor or invited speaker.

BODO E. KNUDSEN, MD, FRCSC

Dr. Bodo Knudson is the Director of the OSU Comprehensive Kidney Stone Program and Vice-Chair of Clinical Operations in the Department of Urology at the Ohio State University. Dr. Knudson has been at OSU for over seven years; prior to this he did his residency training at the University of Manitoba and his fellowship training in Endourology and Stone Disease at the University of Western Ontario under the supervision of Drs. John Denstedt and Stephen Pautler. Dr. Knudson’s research interests include laser use in urology, simulation, medical device evaluation and impact on patient outcomes. Dr. Knudson is currently serving as the Secretary of the Ohio Urological Society, is the Ohio representative to the Northcentral Section’s Young Urologist Committee, and is a member of the R.O.C.K. Society.

CHERYL T. LEE, MD

Dr. Lee is currently an Associate Professor of Urology at the University of Michigan where she is the Robert H. and Eva M. Moyad Professor of Urology, and co-director of the Bladder Cancer Program. She is dedicated to improving the care of bladder cancer patients through advocacy, education and research. She has served as President of the Scientific Advisory Board of the Bladder Cancer Advocacy Network as well as Vice Chairman, Chairman, and Past-Chairman of the Bladder Cancer Think Tank. She is active in the education of urologists maintaining a postgraduate course at the annual meeting of the AUA, and has served on the AUA Curriculum Committee, the AUA Program Committee, the ABU/AUA Examination Committee, and the Oncology Knowledge Assessment Test Committee. She is currently the Urologic Oncology Fellowship Director at the University of Michigan. She remains an active member of the Board of Directors of the Society of Urologic Oncology and has served as Treasurer, Secretary, Vice President, and currently, as President of the National Medical Association R. Frank Jones Urological Society. Her main research interest is the improvement of quality of life and surgical outcomes for bladder cancer patients.

PAUL RUSSO, MD

Dr. Paul Russo is a graduate of Columbia University College of Physicians and Surgeons and trained in surgery and urology at Washington University School of Medicine in St. Louis, Mo. He completed a 4 year fellowship in basic research and urological oncology under the late Dr. Whitmore. He currently is an Attending Surgeon on the Urology Service at Memorial Sloan Kettering Cancer Center and Professor of Urology at the Weill Cornell School of Medicine in New York City. Dr. Russo leads a multidisciplinary clinical kidney cancer research team which collaborates with many departments within MSKCC and as well as extramural institutions. His main interests include the impact of kidney surgery on renal function, expanding the indications for partial nephrectomy, the role of surgery in locally advanced and metastatic renal cancer, the development of clear cell specific PET imaging, and the role of chronic kidney disease in the development of kidney cancer.

LI-MING SU, MD

Dr. Su completed his urology residency at the New York Presbyterian Hospital-Cornell and his fellowship in robotics and laparoscopic surgery at Johns Hopkins. He served eight years on faculty at the Brady Urological Institute of Hopkins before coming to the University of Florida as Chief of the Division of Robotic and Minimally Invasive Urologic Surgery where he now leads a team of five minimally invasive surgeons. His clinical interests are in minimally invasive surgical therapies for kidney cancer and robotic prostatectomy for prostate cancer. Dr. Su’s research focuses on exploring image-guided surgery for prostate and kidney cancer, robotic simulation and virtual reality and trialing new minimally invasive biomedical technology. He has authored over 75 peer reviewed manuscripts and multiple book chapters and has received audio-visual awards for topics of laparoscopic prostate and kidney surgery.
Scientific Program

THURSDAY, SEPTEMBER 13, 2012

6:30 – 7:30 a.m.

INDUSTRY SPONSORED BREAKFAST SYMPOSIUM

7:30 a.m.

OPENING GREETINGS

Hassan Razvi, President, Northeastern Section
Dennis Pessis, President, American Urological Association
Joseph Chin, President, Canadian Urological Association

7:45 – 8:30 a.m.

PLENARY I

Management of the Incontinent Woman: How do Guidelines and FDA Warnings Impact How We Advise Our Patients?

In the AUA Guidelines for the Surgical Management of Stress Urinary Incontinence (SUI) published in 2009 midurethral synthetic slings (MUS) were said to have comparable efficacy to autologous slings. The urologist who primarily used MUS procedures could appropriately use the guidelines as justification that they were offering the right operation to their SUI patients. In 2011, the FDA issued a second notification on the serious complications associated with the use of vaginal mesh to treat prolapse and SUI. This notification caused some surgeons to use mesh and many patients think that they don’t want a mesh procedure. In this presentation, the role of the MUS and alternative treatments will be discussed taking into account success rates, complications, and treatment of failures.

E. Ann Gormley – Dartmouth-Hitchcock Medical Center

8:30 – 8:45 a.m.

RESIDENT DEBATE

Traditional vs. Mesh Repairs
Moderators: E. Ann Gormley and Elise De

8:45 – 9:15 a.m.

PLENARY II

Aggressive Kidney Cancer – What To Do?

The role of surgical resection in the management of locally advanced RCC, RCC involving the vena cava and locally recurrent RCC will be discussed. For patients with metastatic disease, metastasectomy, cytoreductive nephrectomy, and adjuvant and neoadjuvant clinical trials will be discussed.

Paul Russo – Memorial Sloan Kettering Cancer Institute

9:15 – 9:45 a.m.

PANEL

What To Do With a Small Renal Mass?
Michael Jewett, Gennady Bratslavsky and Wes Kassouf
Moderator: Paul Russo

9:45 – 10:15 a.m.

BREAK

10:15 – 10:45 a.m.

PLENARY III

ESWL: Is it Dead?

Both improvements in technology and published medical evidence have resulted in an increase in ureteroscopic procedures for stone disease. Furthermore, expanding indications for PCNL have been established. Given these scenarios, is there still a role shockwave lithotripsy in the treatment of renal calculi?

Bodo E. Knudsen – Ohio State University

10:45 – 11:30 a.m.

PANEL

Difficult Cases in Endourology
Tim Averch, Jim Watterson and Mark White
Moderator: Bodo Knudsen

11:30 a.m. – 12:30 p.m.

INDUSTRY SPONSORED LUNCH SYMPOSIUM

Decisions Points: Practical Considerations for Bone Health in Patients with Prostate Cancer
Sponsored by

AMGEN

12:30 – 1:30 p.m.

EXHIBIT HALL SNEAK PEEK

NEW Resident Laparoscopic Skills Competition (Preliminary Rounds)

1:30 – 2:00 p.m.

PLENARY IV

Advances in Pediatric Urology

The management of VUR has changed significantly in the past decade. The need for follow-up VCUG and prophylactic antibiotics is being re-examined and re-evaluated on an ongoing basis. Reflux is a wide spectrum anomaly and should be managed according to the potential risk for recurrent infections and renal injury. The factors that determine these risks will be addressed and a proposed VUR score that will assist the practicing urologist in decision making regarding the need for further VCUG, ongoing antibiotics, or surgical intervention, will be presented. I will also address the role of minimally invasive surgery for VUR correction looking at the outcomes of laparoscopic and endoscopic approaches.

Antoine E. Khoury - University of California, Irvine

2:00 – 2:30 p.m.

PANEL

Controversies in Pediatrics
Barry Kogan, Luis Guerra, Karen Psooy and Luis Braga
Moderator: Antoine Khoury
2:30 – 2:45 p.m.

RESIDENT DEBATE

Pediatrics

Moderators: Antoine Khoury and Karen Psooy

2:45 – 3:15 p.m.

BREAK IN EXHIBIT HALL

3:15 – 5:00 p.m.

CONCURRENT MODERATED POSTER SESSIONS I & II

MODERATED POSTER SESSION I: ONCOLOGY 1

3:35 p.m.

P1 – The Impact Of a Sensitivity Adapted Antimicrobial Prophylactic Strategy on Prostate Biopsy Sepsis


University of Ottawa, Ottawa, ON, Canada.

3:38 p.m.

P2 – The Impact Of Concomitant Carcinoma In Situ On Upstaging Following Radical Cystectomy For Bladder Cancer


1McGill University, Montreal, QC, Canada, 2University of Western Ontario, London, ON, Canada, 3Laval University, Quebec, QC, Canada, 4University of Alberta, Edmonton, AB, Canada, 5Dalhousie University, Halifax, NS, Canada, 6University of Ottawa, Ottawa, ON, Canada, 7University of Montreal, Montreal, QC, Canada, 8University of Manitoba, Winnipeg, MB, Canada.

3:41 p.m.

P3 – Bone Scans Associated with Prolonged Overall Survival in Patients with Metastatic Castrate Resistant Prostate Cancer Treated With Sipuleucel–T

E. David Crawford, Adam S. Kibel, Albert Azose, Robert B. Sims, Todd DeVries, Ron S. Israeli.

1University of Colorado, Denver, CO, USA, 2Dana-Farber Cancer Institute, Boston, MA, USA, 3Seattle Radiologists, Seattle, WA, USA, 4Dendreon, Seattle, WA, USA, 5Staten Island Urologic Oncology, Staten Island, NY, USA.

3:44 p.m.

P4 – Overall Survival Benefit with Sipuleucel–T by Baseline PSA: Exploratory Analysis from the IMPACT Trial

Robert B. Sims, Paul Schellhammer, Gerald Chodak, James B. Whitmore, Philip W. Kantoff.

1Dendreon, Seattle, WA, USA, 2Eastern Virginia Medical School / Urology of Virginia, Norfolk, VA, USA, 3Louis A Weiss Memorial Hospital, Chicago, IL, USA, 4Dana-Farber Cancer Institute of Harvard Medical School, Boston, MA, USA.

3:47 p.m.

P5 – Prostate-specific Antigen Screening For Prostate Cancer And The Risk Of Overt Metastatic Disease At Presentation: Analysis Of Trends Over Time

Emil Scosyrev, Guan Wu, Supriya Mohile, Edward Messing.

University of Rochester, Rochester, NY, USA.

3:50 p.m.

P6 – Non-Congruent UroVysion, Cytology and Cystoscopy in Detecting Urothelial Carcinoma: Initial Evaluation in Clinical Practice

Sara Spettel, Timothy Fong, Hugh Fisher.

Albany Medical Center, Albany, NY, USA.

3:53 p.m.

P7 – Interferon Regulatory Factor (IRF) - 8 - An Old-Fashioned Transcription Factor Turns Significant Clinical Prognosticator In Advanced Kidney Cancer Patients

Thomas Schwaab, Austin Miller, Gissou Azadaftari, Jeremy Waight, Mohammed Habbiby, Scott Abrams.

RPCI, Buffalo, NY, USA.

3:56 p.m.

P8 – The Effect of Surgeon Experience on Radical Prostatectomy Outcomes

David R. Harvey, Rodney H. Breau, Christopher Morash, Ronald G. Gerdizen, Ranjeeta Mallick, Michael Horrigan, Kelsey Witiuk, Dean Ferguson, Ilias Cagiannos.

1University of Ottawa, Ottawa, ON, Canada, 2The Ottawa Hospital Division of Urology, Ottawa, ON, Canada, 3The Ottawa Hospital Research Institute, Ottawa, ON, Canada.

3:59 p.m.

P9 – A Population Based Analysis Of Pathological Outcomes Following Radical Prostatectomy In Academic Vs .Non-academic Institutions

Jasmir Nayak, Elke Mau, Darrel Drachenberg, Derek Soderman, Kimi Guilbert, Giselle Mak, Giselle Mak, Pascal Lambert, Harvey Quon.

University of Manitoba, Winnipeg, MB, Canada.

4:02 p.m.

P10 – PSA Bounce Following Prostate Brachytherapy For Clinically Localized Prostate Adenocarcinoma: A Single Institution Study With Minimum 3 Years Follow-up

Jasmin Nayak, Aldrich Ong, Jeff Bews, Amit Chowdhury, Darrel Drachenberg.

University of Manitoba, Winnipeg, MB, Canada.
Scientific Program

4:05 p.m.

P11 – Association Of Multifocality With Different Histological Subtypes Of Renal Cortical Tumors
Osama Zaytoun, Stephen Blakely, Mourad Abouelleil, Mickey Daugherty, Oleg Shapiro, Gustavo Delarosa, Steve Landas, Gennady Bratslavsky.

SUNY Upstate, Syracuse, NY, USA.

4:08 p.m.

P12 – Peri-operative Chemotherapy for Bladder Cancer in Ontario: A Population-Based Study

Queen’s University, Kingston, ON, Canada.

4:11 p.m.

P13 – Active Surveillance (AS): Initial Comparison of Management Strategies

Roswell Park Cancer Institute, Buffalo, NY, USA.

4:14 p.m.

P14 – Validation of the 2009 UICC/AJCC TMN Staging System for Renal Cell Carcinoma with Venous Extension

1Hospital Universitario Puerta de Hierro-Majadahonda, Universidad Autónoma de Madrid, Madrid, Spain, 2Memorial Sloan Kettering Cancer Center (MSKCC), New York, NY, USA, 3San Raffaele, University Vita-Salute, Milan, Italy, 4Sloan Kettering Cancer Center (MSKCC), New York, NY, USA, 5Hospital Universitario Puerta de Hierro-Majadahonda, Universidad Autónoma de Madrid, Madrid, Spain, 6Moler School of Medicine, University of Miami, Miami, FL, USA, 7Hospital General Universitario Gregorio Marañón, Madrid, Spain, 8University of Heidelberg Medical School, Heidelberg, Germany, 9University of California, Davis Medical Center, Sacramento, CA, USA, 10Hospital San Raffaele, University Vita-Salute, Milan, Italy, 11Fundación Puigvert, Barcelona, Spain, 12Wayne State University, Detroit, MI, USA, 13Moler School of Medicine, Miami, FL, USA, 14Maggiore d Ila Carità Hospital, University of Eastern Piedmont, Novara, Italy, 15Lahey Clinic, Burlington, MA, USA.

4:17 p.m.

P15 – Statin Use And The Risk Of Biochemical Recurrence Of Prostate Cancer After Definitive Local Therapy: A Meta-analysis Of Eight Cohort Studies

University of Rochester, Rochester, NY, USA.

4:20 p.m.

P16 – Indentification Of Thrombotic Risk For Men With Prostate Cancer: A Pilot Study Evaluating Hemostatic Staus Using Thromboelastography
D. Robert Siemens, Mazen Toukh, Maha Othman.

Queen’s University, Kingston, ON, Canada.

4:23 p.m.

P17 – Quality Of Care Indicators and Their Related Outcomes: A Population-based Validation Study Of Radical Prostatectomy
Colleen Webber, D. Robert Siemens, Michael Brundage, Patti Groome.

Queen’s University, Kingston, ON, Canada.

4:26 p.m.

P18 – A Randomized, Crossover Trial Assessing Tolerability of Intramuscular and Subcutaneous Administration of Gonadotropin Releasing Hormone Analogues in Patients With Advanced Prostate Cancer
Neal D. Shore, Scott Olsen.

1Carolina Urologic Research Center, Myrtle Beach, SC, USA, 2Watson Laboratories, Parsippany, NJ, USA.

4:29 p.m.

P19 – The Association Between Neurovascular Bundle Preservation and Positive Surgical Margins During Radical Prostatectomy
Praveen Moodley, Ilias Cagiannos, Mark Preston, Jonathan Moles, Christopher Morash, Ronald Gerridzen, Kelsey Witiuk, Dean Fergusson, Rodney Brea.

University of Ottawa, Ottawa, ON, Canada.

4:32 p.m.

P20 – Risk Of Blood Transfusion During Radical Cystectomy
Mark Spurrell, Ranjeeta Mallick, Dean Fergusson, Kelsey Witiuk, Chris Morash, Ilias Cagiannos, Rodney H. Brea.

1University of Ottawa, Ottawa, ON, Canada, 2Ottawa Hospital Research Institute, Ottawa, ON, Canada.
Scientific Program

MODERATED POSTER SESSION II: LAPAROSCOPY/ROBOTICS; STONES/ENDOUROLOGY; EDUCATION

3:35 p.m.

P21 – Prospective, Randomized Use Of The VLOC Vescicourethral Anastomosis During Robot Assisted Radical Prostatectomy: Long-term Followup
Tal Ben-Zvi, Daniel Liberman, Quoc-Dien Trinh, Assaad El-Hakim, Kevin Zorn.
University of Montreal, Montreal, QC, Canada.

3:38 p.m.

P22 – Comparison Of Urologic Complications Related To Pure Laparoscopic vs. Robotic-Assisted Hysterectomy
Kathir Balakumaran1, Jawid Darvesh1, Louis H. Eichel2.
1Saba University School of Medicine, Saba, Netherlands, 2Center for Urology, Rochester General Hospital, Rochester, NY, USA.

3:41 p.m.

P23 – Robot-Assisted Radical Cystectomy In Female Patients: The RPCI Experience
Aabroo J. Khan, Syed Johar Raza, Shabnam Rehman, Rakeeba Din, Andrew P. Stegemann, Yi Shi, Gregory E. Wilding, Khurshid A. Guru.
Roswell Park Cancer Institute, Buffalo New York, USA.

3:44 p.m.

P24 – Understanding Avoidance, Refusal And Abandonment Of Chemotherapy Before & After Cystectomy For Bladder Cancer
Rakeeba Din, Shabnam Rehman, Faris S. Azzouni, Aabroo J. Khan, Andrew P. Stegemann, Yi Shi, Gregory Wilding, Ellis G. Levine, Saby George, Roberto Pili, Donald L. Trump, Khurshid A. Guru.
Roswell Park Cancer Institute, Buffalo New York, USA.

3:47 p.m.

P25 – Performance and Durability Evaluation of the Robotic Surgical Simulator (RoSS) at an Academic Training Center
Rakeeba Din, Shabnam Rehman, Syed J. Raza, Aabroo J. Khan, Thenkurussi Kesavadas, Yong Won Seo, Andrew P. Stegemann, Khurshid A. Guru.
Roswell Park Cancer Institute, Buffalo New York, USA.

3:50 p.m.

P26 – A Review Of Our Experience With Robot Assisted Radical Prostatectomy
Ahmed Ghazi, MD, FEBU, Jean Joseph, MD, MBA.
University of Rochester, Rochester, NY, USA.

3:53 p.m.

P27 – Using Simulation-Based Robotic Training: Is It Penny Wise Or Pound Foolish?
Aabroo J. Khan, Shabnam Rehman, Syed Johar Raza, Rakeeba Din, Andrew Stegemann, Kamran Ahmad, Lynn Dio, Michael Trznadel, Thenakrussi Kesavadas, James L. Mohler, Khurshid A. Guru.
Roswell Park Cancer Institute, Buffalo New York, USA.

3:56 p.m.

P28 – Factors affecting re-admission following Robot-assisted Radical Cystectomy: Results from the International Robotic Cystectomy Consortium
1Roswell Park Cancer Institute, Buffalo, NY, USA, 2Maine Medical Center, Portland, ME, USA, 3Guy’s & St Thomas Hospitals, London, United Kingdom, 4Bassett Healthcare, Cooperstown, NY, USA, 5Henry Ford Health System, Detroit, MI, USA, 6Ankara Ataturk Training & Research Hospital, Ankara, Turkey, 7City of Hope, Duarte, CA, USA, 8Washington University School of Medicine, St. Louis, MO, USA, 9Washington University School of Medicine, St. Louis, NY, USA, 10Eötvös University School of Medicine, Atlanta, GA, USA, 11Fundacio Puigvert, Barcelona, Spain, 12Yonsei University Health System Severance Hospital, Seoul, Korea, Democratic People’s Republic of, 13Arthur Smith Institute for Urology, Long Island, NY, USA, 14Saarland University Clinic, Homburg, Germany, 15Karolinska University, Stockholm, Sweden, 16Karolinska University, Stockholm, Sweden, 17Loyola University Medical Center, Maywood, IL, USA.

3:59 p.m.

P29 – The Surgical Management Of Renal Stone Disease Among Spinal Cord Injury Patients
Blyane Welk.
Western University, London, ON, Canada.

4:02 p.m.

P30 – Changes in the Surgical Management of Kidney Stone Disease: A Population Based Time Series Analysis
Michael Ordon1, Refik Saskirin, Muhammad Mamdani1, David Urbach1, R. John D’A. Honey1, Kenneth T. Pace1.
1St. Michael’s Hospital, University of Toronto, Toronto, ON, Canada, 2Institute for Clinical and Evaluative Sciences, Toronto, ON, Canada, 3University Health Network, University of Toronto, Toronto, ON, Canada.

4:05 p.m.

P31 – Pulsed Fluoroscopy in Ureteroscopy and Percutaneous Nephrolithotomy
Mohamed A. Elkousy, Walid Shahrour, Sero Andonian.
McGill University Health Center, Montreal, QC, Canada.
Scientific Program

4:08 p.m.
P32 – Effect of Kidney Stone Clinic on Hyperoxaluria
Zeyad R. Schwen, Julie M. Riley, Timothy D. Averch.
University of Pittsburgh Medical Center, Pittsburgh, PA, USA.

4:11 p.m.
P33 – Does A Routine Baseline Plain Radiograph Influence the Need for Subsequent Imaging Studies in Patients with Ureteral Calculi?
Kirsten Foell, Michael Ordon, Daniela Ghiculete, R John D’A Honey, Kenneth T. Pace.
St. Michael’s Hospital, University of Toronto, Toronto, ON, Canada.

4:14 p.m.
P34 – Nephrolithiasis and Pregnancy: Has the Incidence Been Rising?
Anne G. Dudley, Julie M. Riley, Michelle J. Semins.
University of Pittsburgh Medical Center, Pittsburgh, PA, USA.

4:17 p.m.
P35 – Day Of Surgery Cancellation Rates In Urology: Identification Of Modifiable Factors
Robert J. Leslie.
Queen’s University, Kingston, ON, Canada.

4:20 p.m.
P36 – WITHDRAWN

4:23 p.m.
P37 – The Newly Graduated Canadian Urologist: Overtrained and Underemployed?
Blayne Welk1, Ron Kodama1, Andrew MacNeil2.
1Western University, London, ON, Canada, 2University of Toronto, Toronto, ON, Canada, 3University of British Columbia, Vancouver, BC, Canada.

4:26 p.m.
P38 – On Screen Frame Of Reference System And Standardized Communication Promotes Safe And Efficient Laparoscopic Teaching: A Three Armed Randomized Control Trial
Rami Elias, Kiara Hennessey, Bechir Hage, David Williams, Forough Farrokhyar, Edward Matsumoto.
McMaster University, Hamilton, ON, Canada.

4:29 p.m.
P39 – Pain Management in Urological Surgery: A National Survey of Canadian Chief Residents
Jonathan H. Pace.
Queens University, Kingston, ON, Canada.

4:32 p.m.
P40 – The Evolution of Urology in Nicaragua
Emma E. Bendana, Constantino Fernandez.
University of Rochester, Rochester, NY, USA.

4:35 p.m.
P41 – Social Networking In The Bedroom: The Beliefs, Barriers And Prevalence Of Sexual Dysfunction Among Young Men And Women
Helen R. Levey1, Arthur Burnett2, Trinity J. Bivalacqua3.
1Department of Urology, University of Rochester Medical Center, Rochester, NY, USA, 2Johns Hopkins Medical Institutions, The James Buchanan Brady Urological Institute, Baltimore, MD, USA.

5:00 – 6:00 p.m.
INDUSTRY SPONSORED SYMPOSIUM RECEPTION
Provenge: Activate the Power of the Immune System to Extend Survival
Sponsored by

6:00 – 7:00 p.m.
EXHIBIT HALL GRAND OPENING RECEPTION

Publication of 2012 Abstracts

The Section is pleased to announce that all accepted abstracts of the 2012 annual meeting have been published in the August issue of the Canadian Urological Association Journal (CUAJ). A copy of this issue of CUAJ will be distributed with this program book.

The Canadian Urological Association Journal (CUAJ) is owned and officially endorsed by the Canadian Urological Association. CUAJ is a bi-monthly publication and is searchable on PubMed, with full-text articles on PubMed Central and on the newly created CUAJ website (www.cuaj.ca). CUAJ is also covered in the Science Citation Index Expanded (also known as SciSearch) and the Journal Citation Reports/Science Edition provided by Thomson Reuters. Its recent impact factor is 1.237.

For additional information on submitting manuscripts or subscription information, contact:

JOSEPHINE SCIORTINO
Editorial Director, CUAJ
1155 University, Suite 1303
Montréal, QC, Canada H3B 3A7
Tel: +1 514 395-0376, ext. 40
Fax: +1 514 395-1664
Email: josephine.sciortino@cuaj.org
Web: www.cuaj.ca
Scientific Program

FRIDAY, SEPTEMBER 14, 2012

6:30 – 7:30 a.m.
INDUSTRY SPONSORED BREAKFAST SYMPOSIUM
Biochemical Suppression Starting Day 1
Sponsored by

6:30 – 8:00 a.m.
5K FUN RUN/WALK

7:30 – 7:45 a.m.
BEST-OF-POSTERS
Presented by moderators of Thursday’s poster sessions

7:45 – 8:15 a.m.
SECTION STARS
Sero Andonian, 2009 Young Investigator Research Grant Recipient
Radiation Safety in Urology: What have I learned?

PRIZE WINNING ESSAYS
First Place
Loss of PPM1A is associated with pathologic hyperactivation of TGF-beta/SMAD signaling in obstructive uropathy
Amy D Dobberfuhl, MD – Albany Medical College

Second Place
Incidence of Bladder Cancer as a Secondary Malignancy in Patients Treated With Radiation for Uterine Cancer
Janet Baack Kukreja, MD – University of Rochester Medical Center

Tied for Third Place
Perineural Invasion and Lethal Prostate Cancer
Piotr Zareba, MD – McMaster University

Tied for Third Place
Long-Term Use of Solifenacin in Pediatric Patients with Overactive Bladder: Extension of a Prospective Open-Label Study
Geneviève Nadeau, MD – Université Laval

8:15 – 9:00 a.m.
PLENARY V
The Evidence Based Medicine Revolution: A Surgeon’s Perspective
Evidence-based medicine has recently been termed one of the top 10 discoveries in medicine. Changing the paradigm from ‘eminence-based’ to ‘evidence-based’ care requires a focus on the value of high quality evidence and its impact on patient care. This talk will highlight the advantages of EBM, the challenges of conducting high quality research, and the opportunities for surgeons and researchers to lead a major shift in paradigm in Urology.
Mohit Bhandari – McMaster University

9:00 – 9:45 a.m.
PLENARY VI
Improving the Quality of Care Among Men with Prostate Cancer
The management of prostate cancer remains a daunting challenge. Many men diagnosed with the disease will not die of it, even without any intervention, opening the door to potential over-treatment with its attendant costs and morbidities. However, it is the 2nd most common cancer killer in men, suggesting the need for aggressive treatment in some. Recent improvements in techniques and technology have partially mitigated some of the consequences of surgery. However, tremendous variation in outcomes persist. Efforts to minimize these consequences remains a priority for improving the quality of prostate cancer care.
Brent Hollenbeck, MD – University of Michigan

PANEL
Surgical Quality Assurance – Focus on Prostate Cancer
Neil Fleshner and Andrew Evans
Moderator: Brent Hollenbeck

9:45 – 10:15 a.m.
BREAK IN EXHIBIT HALL
Sponsored by

10:15 – Noon
CONCURRENT MODERATED POSTER SESSIONS III & IV

MODERATED POSTER SESSION III: ONCOLOGY 2
10:35 a.m.
P42 – External Validation of a Preoperative Multivariable Model Used for Prediction of Nonorgan Confined Upper Tract Urothelial Carcinoma
Kevin J. Rycyna, Jeffrey A. Larson, Benjamin Davies.
University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
10:38 a.m.

**P43 – Incidence of Bladder Cancer as a Secondary Malignancy in Patients Treated with Radiation for Uterine Cancer**

Janet Baack Kukreja, Emelian Scosyrev, Edward Messing, Guan Wu.

University of Rochester, Rochester, NY, USA.

10:41 a.m.

**P44 – Compared to Radical Nephrectomy, Nephron Sparing Surgery Offers a Long-Term Survival Advantage in Patients Between the Ages of 20 and 44 with Renal Cell Carcinomas (<4cm): An Analysis of the SEER Database**

Michael Daugherty, Gennady Bratslavsky.

SUNY Upstate Medical University, Syracuse, NY, USA.

10:44 a.m.

**P45 – Comparative Morbidity Between Salvage High Intensity Focused Ultrasound and Cryotherapy for Radio-recurrent Prostate Cancer**


1Dammam University, Dammam, Saudi Arabia, 2London Health Science Center, London, ON, Canada.

10:47 a.m.

**P46 – High Intensity Focused Ultrasound Treatment for Radio-recurrent Localized Prostate Cancer: Predictors for Outcome**


1Dammam University, Dammam, Saudi Arabia, 2London Health Science Center, London, ON, Canada.

10:50 a.m.

**P47 – The Effect Of Alcohol Consumption On Post-prostatectomy Health Related Quality Of Life Outcomes**

Ariel K. Fredrick, Michael A. Poch, Diana C. Mehedint, Rebecca L. O’Malley, Levi Ross, Chi-Chen Hong, James L. Mohler, Khurshid A. Guru, Willie Underwood, III.

Roswell Park Cancer Institute, Buffalo, NY, USA.

10:53 a.m.

**P48 – Investigation of Complex Cystic Renal Masses Using Magnetic Resonance Imaging: A Pilot Study**


The University of Western Ontario, London, ON, Canada.

10:56 a.m.

**P49 – The Opioid Receptor Antagonist Alvimopan Minimizes Postoperative Ileus following Radical Cystectomy: An Update**

Joel D. Bigley, Jamie T. Uy, Jodi K. Maranchie, Jeffrey R. Gingrich, Benjamin J. Davies, Ronald L. Hrebinko.

University of Pittsburgh, Pittsburgh, PA, USA.

10:59 a.m.

**P50 – Poor Erectile Function Pre-Prostatectomy and Nerve Sparing: Is It Worthwhile?**

Francisco J. Garcia1, Linda Notte1, Gerald Brock1, Edward D. Matsumoto1, Stephen E. Pautler1.

1University of Western Ontario, London, ON, Canada, 2McMaster University, Hamilton, ON, Canada.

11:02 a.m.

**P51 – Repeat Biopsy Results And Strategy In Patients With High Grade Prostatic Intraepithelial Neoplasia On Initial Prostate Needle Biopsy**

Alexa Y. Chai, Kent Chevol, Michael Duff.

University at Buffalo, Buffalo, NY, USA.

11:05 a.m.

**P52 – Understanding Prostate Anatomy: Defining Anatomical Variants**

Shawna L. Boyle1, M Kim1, E Matsumoto1, K Pace1, G Kozac, B Welk1, S Pautler1.

1Western University, London, ON, Canada, 2McMaster, Hamilton, ON, Canada, 3University of Toronto, Toronto, ON, Canada, 4University of Calgary, Calgary, AB, Canada.

11:08 a.m.

**P53 – An Alternative Technique For Localizing Renal Masses During C.T Guided Percutaneous Cryoablation In Patients With Renal Impairment**

Ahmed Ghazi, George Holland, Erald Erturk.

University of Rochester, Rochester, NY, USA.

11:11 a.m.

**P54 – Primary Endoscopic Management of Upper Tract Urothelial Carcinoma**


UPMC, Pittsburgh, PA, USA.

11:14 a.m.

**P55 – BCG Therapy as a Predictor of Recurrence and Progression: A Single Institution Retrospective Study**

Zurab Davili, Jay Reeder, Zahi Makhuli, Imad Nsouli.

SUNY Upstate Medical University, Syracuse, NY, USA.
11:17 a.m.
**P56 – Active Prostate Cancer Screening In A Urology Practice Versus Community Based Care: Implications For Diagnosis**
Gaurav Rao, Ramkissen Narayanan, Michael Duff, K. Kent Chevli.
University at Buffalo School of Medicine, Buffalo, NY, USA.

11:20 a.m.
**P57 – Short Term Efficacy of Renal Tumor Cryoablation**
John M. Rutkowski, Ostap Dovirak, Kent Chevli, Nikhil Patel, Sadasiv Shenoy.
University at Buffalo, Buffalo, NY, USA.

11:23 a.m.
**P58 – Micropapillary Variant of Urothelial Carcinoma: A Clinicopathological Analysis**
University of Pittsburgh, Pittsburgh, PA, USA.

11:26 a.m.
**P59 – Pathological Features of Surgically Managed Small Renal Lesions: Analysis of Contemporary Series**
Andres F. Correa, Bishop Gayed, Anil Parwani, Jodi Maranchie.
University of Pittsburgh, Pittsburgh, PA, USA.

11:29 a.m.
**P60 – Prostate Biopsy Perineural Invasion is not Independently Associated with Positive Surgical Margins Following Open Radical Prostatectomy**
Benjamin T. Ristau, Jeffrey J. Tomaszewski, Yi-Fan Chen, Marnie Bertolet, Elen Woldemichael, Joel B. Nelson.
UPMC, Pittsburgh, PA, USA.

11:32 a.m.
**P61 – Adrenal Involvement in Renal Cell Carcinoma: Avoiding Unnecessary Adrenalectomy**
Stephen Blakely, Osama Zaytoun, Mickey Daugherty, Steve Landas, Gennady Bratslavsky, Oleg Shapiro.
Upstate Medical University, Syracuse, NY, USA.

10:38 a.m.
**P63 – Transvaginal Repair Of Primary Versus Recurrent Vesicovaginal Fistulas: There Is No Difference In Outcome**
Dmitriy Nikolovskiy, Thomas Pshak, Brian Flynn.
1SUNY Upstate Medical University, Syracuse, NY, USA; 2University of Colorado, Aurora, CO, USA.

10:41 a.m.
**P64 – Retubularizing the Augmentation Ileocystoplasty Pouch to Form an Ileal Conduit Urinary Diversion**
Peter Massaro, Jerzy Gajewski, Greg Bailly.
Dalhousie University, Halifax, NS, Canada.

10:44 a.m.
**P65 – Sacral Neurmodulation Failures**
Michelle Chang, Jerzy Gajewski.
Dalhousie University, Halifax, NS, Canada.

10:47 a.m.
**P66 – Urethral Regurgitation Discovered Sonographically as the Etiology for Intractability of CPPS and Interstitial Cystitis**
Roger E. Vega.
UPMC St. Margaret, Kittanning, PA, USA.

10:50 a.m.
**P67 – Efficacy and Safety of Oxybutynin Transdermal Gel (84 mg or 56 mg/day) in Patients with Urgency and/or Mixed Urinary Incontinence: Results of a Randomized, Double-Blind Placebo-Controlled Study**
1Hudson Valley Urology, Poughkeepsie, NY, USA; 2University of Chicago, Pritzker School of Medicine, Chicago, IL, USA; 3Women’s Health Specialty Care, Farmington, CT, USA.

10:53 a.m.
**P68 – Combined Anticholinergic Therapy with Long Term Followup in Refractory Overactive Bladder: Quality of Life Assessment and Economics of Care**
Susan Marshall, Kevin Pranikoff.
University at Buffalo, Buffalo, NY, USA.

10:56 a.m.
**P69 – A Novel, Patient-managed Neuromodulation System (PMNS) Using A Transdermal Patch For Treatment Of Overactive Bladder (OAB) With Urgency Urinary Incontinence (UUI)**
Roger Dmochowski, Dennis Miller, Michael Kennelly, Michael Phillips, Tiffany Sotelo, Scott MacDiarmid, Kenneth Peters.
1Vanderbilt University, Nashville, TN, USA; 2Wheaton Franciscan Healthcare, Wauwatosa, WI, USA; 3McKay Urology, Charlotte, NC, USA; 4The George Washington University, Washington, DC, USA; 5Alliance Urology Specialists, Greensboro, NC, USA; 6Beaumont Hospital, Royal Oak, MI, USA.
10:59 a.m.

P70 – Polymorphism Of Scn9a Gene Is More Frequent In Bladder Pain Syndrome /Interstitial Cystitis Biopsy Specimens And Associated With Higher Pain Scores

Jay Reeder	extsuperscript{1}, Robert Mayer	extsuperscript{2}.

	extsuperscript{1}SUNY Upstate Medical University, Syracuse, NY, USA, 	extsuperscript{2}University of Rochester, Rochester, NY, USA.

11:02 a.m.

P71 – WITHDRAWN

11:05 a.m.

P72 – Estimating Differential Renal Function using Ellipsoid Approximation of Renal Volume on Computed Tomography

Laura N. Nguyen, Fadi Kamal, Brian Blew.

University of Ottawa, Ottawa, ON, Canada.

11:08 a.m.

P73 – A Retrospective Review of Prophylactic vs Selective Ureteral Stenting in Renal Transplant Patients

Michael Ordon, Daniela Ghiculete, Robert Stewart, Kenneth T. Pace, R. John D’A. Honey.

St. Michael’s Hospital, University of Toronto, Toronto, ON, Canada.

11:11 a.m.

P74 – Debilitating Lower Urinary Tract Symptoms in the Post-Renal Transplant Population Can be Predicted Pre-Transplantation


Western University, London, ON, Canada.

11:14 a.m.

P75 – T Cell Repopulation After Thymoglobulin Induction Therapy in High Immunological Risk and DCD Renal Transplant Recipients


Western University, London, ON, Canada.

11:17 a.m.

P76 – A Pilot Study to Determine Penile Oxygen Saturation Before and After Vacuum Therapy in Patients with Erectile Dysfunction After Radical Prostatectomy

Charles Welliver	extsuperscript{1}, Joseph Aluka	extsuperscript{2}, Andrew McCullough	extsuperscript{3}.

	extsuperscript{1}Albany Medical Center, Albany, NY, USA, 	extsuperscript{2}New York University, New York City, NY, USA.

11:20 a.m.

P77 – Prevention of Pituitray Gonadotropin Supression During Exogenous Testosterone Replacement By Concomitant Aromatase Inhibitor Administration

Clay Mechlin, Andrew R. McCullough.

Albany Medical College, Albany, NY, USA.

11:23 a.m.

P78 – Testosterone Pellets (Testopel™) Insertion Results In Sustained Suppression Of Pituitary Gonadotropins (GT)

Himanshu Aggarwal, Jason Frankel, Charles Welliver, Clay Mechlin, Matthew Armstrong, Andrew McCullough.

Albany Medical Center, Albany, NY, USA.

11:26 a.m.

P79 – Aromatase Inhibitors Prolong the Therapeutic Duration of Long Acting Testosterone Pellets (Testopel™)

Andrew R. McCullough, Clay Mechlin.

Albany Medical College, Albany, NY, USA.

11:29 a.m.

P80 – Mid-term Outcomes Of Greenlight Vapor-incision Of The Prostate (VIT): Comparison Of Outcomes To Standard Greenlight 120W HPS Vaporization In Prostate Volumes Greater Than 80cc

Tal Ben-Zvi	extsuperscript{1}, Daniel Liberman	extsuperscript{1}, Pierre-Allain Hueber	extsuperscript{1}, Gagan Gautam	extsuperscript{1}, Tom Dekle	extsuperscript{2}, Kevin Zorn	extsuperscript{2}.

	extsuperscript{1}University of Montreal, Montreal, QC, Canada, 	extsuperscript{2}University of Chicago, Chicago, IL, USA.

11:32 a.m.

P81 – Greenlight-HPS (120w) versus Greenlight XPS (180W) Laser Vaporization Of The Prostate For Benign Prostatic Hyperplasia: A Global, Multi-center Prospective Comparative Analysis


	extsuperscript{1}University of Montreal, Montreal, QC, Canada, 	extsuperscript{2}Westmead Hospital, The University of Sydney, Sydney, Australia, 	extsuperscript{3}Oakwood Annapolis Hospital, Wayne, MI, USA, 	extsuperscript{4}Cornell Weill Medical College and New York Presbyterian Hospital, New York, NY, USA, 	extsuperscript{5}Cornell Weill Medical College and New York Presbyterian Hospital, New York, NY, USA, 	extsuperscript{6}Columbia University, New York, NY, USA, 	extsuperscript{7}The Methodist Hospital, Houston, TX, USA, 	extsuperscript{8}Frimley Park Hospital, Frimley, Surrey, United Kingdom.

12:00 – 1:30 p.m.

LUNCH IN EXHIBIT HALL

Resident Laparoscopic Skills Competition Finals
Scientific Program

1:30 – 2:15 p.m.

GEORGE E. SLOTKIN LECTURE
The Evolution of Testis Cancer Care
This presentation will review current management guidelines and consensus statements as they relate to the common clinical scenarios encountered by the practicing urologist to help them understand the rationale and methods to minimize morbidity while maintaining high survival rates. Dr. Jewett will review the results of their efforts at Princess Margaret Hospital to innovate in surgery, radiotherapy and active surveillance that have contributed to the changes in management over the past 30+ years.

Michael A.S. Jewett – University of Toronto

2:15 – 2:45 p.m.

PANEL
Genitourinary Reconstruction
Blayne Welk and Mang Chen
Moderator: Ron Kodama

2:45 – 3:00 p.m.

BREAK

3:00 – 4:30 p.m.

CONCURRENT MODERATED POSTER SESSIONS V & VI

MODERATED POSTER SESSION V: BASIC SCIENCE

3:20 p.m.

P82 – Combination of Foot Stimulation and Tramadol Treatment Reverses Irritation Induced Bladder Overactivity in Cats
Abhijith D. Mally1, Fan Zhang1, Yosuke Matsuta1, Bing Shen1, Jicheng Wang2, James R. Roppel1, William C. De Groat1, Changfeng Tai1.
1University of Pittsburgh, Pittsburgh, PA, USA; 2Capital Medical University, Beijing, China.

3:23 p.m.

P83 – Inhibition of Bladder Overactivity by a Combination of Tibial Neurnamodulation and Tramadol Treatment in Cats
Jeffrey A. Larson1, Abhijith D. Mally1, Dafe Ogagari, Fan Zhang1, Bing Shen1, Jicheng Wang2, James R. Roppel1, William C. De Groat1, Changfeng Tai1.
1University of Pittsburgh, Pittsburgh, PA, USA; 2Capital Medical University, Beijing, China.

3:26 p.m.

P84 – Systematic Design of a Clinical Grade Dendritic Cell Vaccine For Patients With NY-ESO-1 Expressing GU-Cancers
Thomas Schwaab, Junko Matsuzaki, Mohammed Habiby, Christopher Choi, Joseph Tario, Paul Wallace, Audekunle Odunsi.
RPCI, Buffalo, NY, USA.

3:29 p.m.

P85 – Loss of PPM1A is Associated with Pathologic Hyperactivation of TGF-beta/SMAD Signaling in Obstructive Uropathy
Amy D. Dobberfuhl1, Jessica M. Overstreet2, Badar M. Miani1, Rohan Samarakoon1, Paul J. Higgins2.
1Straton VA Medical Center, Division of Urology, Albany, NY, USA, 2Albany Medical College, Center for Cell Biology and Cancer Research, Albany, NY, USA.

3:32 p.m.

P86 – Disruption Of The Fln Gene In Mouse Proximal Tubule Caused Diverse Renal Tumorigenesis
Jindong Chen1, Kunihiko Futami1, Pengfei Wang1, Isabelle Rubera2, Sok-Kean Kho3, Karl Dykema4, Ping Zhao1, David Petillo1, Brian Cao1, Kun-Liang Guan1, Ximing J. Yang1, Ming Zhou1, Guan Wu1, Michel Tau1, Bart O. Williams2, Bin Tean Teh3, Kyle Furges4.
1University of Rochester, Rochester, NY, USA, 2Tokyo University of Marine Science and Technology, Tokyo, Japan, 3University of Nice-Sophia Antipolis, Nice, France, 4Van Andel Research Institute, Grand Rapids, MI, USA, 5University of California San Diego, La Jolla, CA, USA, 6Northwestern University Feinberg School of Medicine, Chicago, IL, USA, 7Cleveland Clinic, Cleveland, OH, USA, 8National Cancer Centre, Singapore, Singapore.

3:35 p.m.

P87 – Dynamic MRI Urethrography: Fluid Turbulence In A Urethral Stricture Phantom
Jon Moles, Rebecca Thornhill, Wael Shabana, Eric Saltel.
University of Ottawa, Ottawa, ON, Canada.

3:38 p.m.

P88 – The Influence of Urinary pH on Antibiotic Efficacy Against Bacterial Uropathogens
Luo Yang1, Kunjie Wang1, John D. Denstedt1, Peter A. Cadieux1.
1University of Western Ontario, London, ON, Canada, 2West China Hospital of Sichuan University, Chengdu, China.

3:41 p.m.

P89 – Prostate Cancer Microparticles: A Novel Blood-based Prognosticator Of Metastasis
Ali Al-Zahrani1, Hon Sing Leong1, Vladimir Yutkin1, Nicholas E. Power1, Jonathan I. Izawa1, John D. Lewis1, Joseph L. Chin1.
1London Health Sciences Centre, London, ON, Canada, 2University of Alberta, Edmonton, AB, Canada.
3:44 p.m.
P90 – Branching and Invasive Phenotypes of Human Kidney Cancer Cells Require Intracellular Superoxide Generation by Nox4
University of Pittsburgh, Pittsburgh, PA, USA.

3:47 p.m.
P91 – Growth Stimulatory Effects of Antibiotics on Enterococci
Samantha Whiteside, Sumit Dave, Peter A. Cadieux.
University of Western Ontario, London, ON, Canada.

3:50 p.m.
P92 – Urinary Device Attachment of Staphylococcus saprophyticus in the Presence of Sub-Minimal Inhibitory Antimicrobial Concentrations
Varunkumar Bathini, Andrew Fuller, Lee Goneau, Kyle MacDonald, Hassan Razvi, Peter A. Cadieux.
University of Western Ontario, London, ON, Canada.

3:53 p.m.
P93 – Nanoparticle-mediated Delivery of Imaging and Therapeutic Agents
1Albany Medical Center, Albany, NY, USA, 2College of pharmacy, Albany, NY, USA.

3:56 p.m.
P94 – Investigating Ochratoxin A and Biotin Levels in Patients with Renal Carcinoma
Nader Fahmy, Mark Woo, Kyle MacDonald, Lee Goneau, Peter Cadieux, Stephen Pautler.
The University of Western Ontario, London, ON, Canada.

3:59 p.m.
P95 – NADPH Oxidase 4 Expression is Increased in Renal Oncocytoma Relative to Chromophobe Renal Cell Carcinoma
1University of Pittsburgh Medical Center, Pittsburgh, PA, USA, 2University of Pittsburgh, Pittsburgh, PA, USA.

4:02 p.m.
P96 – Antiproliferative Effects of Non Anticoagulant Low Molecular Weight Heparin on Bladder Cancer in Mice
Ardalan E. Ahmad, Sudha Thangirala, Wadad Meimneh, Barbara Zaffo, Tipu Nazeeri, Mousa Shaker, Badar Mian.
1Albany Medical College, Albany, NY, USA, 2Albany College of Pharmacy, Albany, NY, USA.

4:05 p.m.
P97 – Clinicopathological and Molecular Characterization of Renal Cell Carcinomas with Sarcomatoid Differentiation and a Prominent Rhabdoid Phenotype
University of Pittsburgh, Pittsburgh, PA, USA.

4:08 p.m.
P98 – Sub-Minimal Inhibitory Concentrations of Antimicrobials Prime Staphylococcus saprophyticus for Survival Within the Urinary Tract During Prophylaxis
Lee Goneau, Kyle MacDonald, Hassan Razvi, Peter A. Cadieux.
University of Western Ontario, London, ON, Canada.

MODERATED POSTER SESSION VI: PEDIATRICS
3:20 p.m.
P99 – Comparison Between Renal Sonography and Dimercaptoacetic Acid Scintigraphy In Renal Scarring Evaluation
Maryse Marceau-Grimaldi, Christian Côté, Stéphane Bolduc, Marcel Dumont, Katherine Moore.
1Université Laval, Québec, QC, Canada, 2Hôpital Saint-François d’Assise CHUQ, Québec, QC, Canada, 3LOEX, Université Laval, Québec, QC, Canada.

3:23 p.m.
P100 – Cost Analysis Of Pediatric Robotic Assisted and Laparoscopic Pyleoplasty
Daniel P. Casella, Janelle A. Fox, Glenn M. Cannon, Francis X. Schneck, Steven G. Docimo, Michael C. Ost.
University Of Pittsburgh, Pittsburgh, PA, USA.

3:26 p.m.
P101 – Using Oximetry to Monitor Neonatal Testicular Torsion: Another Trial to Be Proved?
Ming-Kuen Lai, Xueke Wang, Hongzhen Wang, Dingjun Fu.
Chang Gung Hospital, Xiamen, China.

3:29 p.m.
P102 – Pediatric Urolithiasis: Recurrence Rates At 5-Years
Michael Lao, Mark D. White, Barry A. Kogan.
Albany Medical College, Albany, NY, USA.

3:32 p.m.
P103 – Outcomes of Hypospasias Repair by Tubularized Incised Plate Urethroplasty in Pediatric Patients: a Single Surgeon Learning Experience
Marie-Pier Deschenes Rompré, Geneviève Nadeau, Katherine Moore, Louis Braga, Stéphane Bolduc.
1Centre Hospitalier de l’Université Laval, Quebec, QC, Canada, 2Mc Master Children Hospital, Hamilton, ON, Canada.
Scientific Program

3:35 p.m.
P104 – A Pilot Randomized Controlled Trial Comparing Botulinum Toxin A versus Anticholinergic Therapy in Non-Compliant Pediatric Neurogenic Bladder
Peter (Zhan Tao) Wang, Sarah Langford, Hassan Razvi, Sumit Dave.
University of Western Ontario, London, ON, Canada.

3:38 p.m.
P105 – Four Missed Torsions and Their Ultrasound Findings
Lorraine M. Liang, William C. Hulbert, Robert A. Mevorach, Jimena Cubillos, Ronald Rabinowitz.
Division of Pediatric Urology, Department of Urology, University of Rochester Medical Center, Rochester, NY, USA.

3:41 p.m.
P106 – Long-Term Use of Solifenacin in Pediatric Patients with Overactive Bladder: Extension of a Prospective Open-Label Study
Geneviève Nadeau, Annette Schroder, Katherine Moore, Lucie Genois, Stéphane Bolduc.
CHUL, Québec, QC, Canada.

3:44 p.m.
P107 – Double Anticholinergic Therapy for Refractory Hyperreflexic Bladder in Children: Long-Term Results of a Prospective Open-Label Study
Geneviève Nadeau, Annette Schroder, Katherine Moore, Lucie Genois, Pascale Lamontagne, Stéphane Bolduc.
CHUL, Québec, QC, Canada.

3:47 p.m.
P108 – Aggressive Inflammatory Myofibroblastic Tumor (IMT) of the Urinary Bladder in Children
Janet Baack Kukreja, Jennifer Gordetsky, Jimena Cubillos, Robert A. Mevorach, Ronald Rabinowitz, William C. Hulbert.
University of Rochester, Rochester, NY, USA.

3:50 p.m.
P109 – Local Penile Skin Flaps for Hypospadias Cripples: Ten Year, Single Center Experience
Janelle A. Fox, Francis X. Schneck.
Children’s Hospital of Pittsburgh of UPMC, Pittsburgh, PA, USA.

3:53 p.m.
P110 – Quality Of Life Evaluation Of Adolescents Born With Bladder Exstrophy Who Underwent Complex Uroinary Reconstruction
Melanie I. Morris, Julie Franc-Guimond, Diego Barrieras, Anne-Marie Houle.
University of Montreal, Montreal, QC, Canada.

3:56 p.m.
P111 – A Comparative Analysis Of Open Versus Retroperitoneoscopic Nephrectomies In The Pediatric Population
Melanie I. Morris, Pierre-Alain Huebert, Julie Franc-Guimond, Anne-Marie Houle, Diego Barrieras.
University of Montreal, Montreal, QC, Canada.

3:59 p.m.
P112 – Total Urogenital Mobilization (tum) Can Be Used In Pubertal And Postpubertal Patients
Melanie I. Morris, Julie Franc-Guimond.
University of Montreal, Montreal, QC, Canada.

4:02 p.m.
P113 – Laparoscopic Pyeloplasty for Ureteropelvic Junction Obstruction in Infants
University of Pittsburgh, Pittsburgh, PA, USA.

4:30 – 6:00 p.m.
NEW MENTORING PROGRAM
How to Take Control of Your Financial Life
Following a networking reception with your peers, join us as the secrets of how to obtain financial success are revealed. This presentation is designed to educate and advise you so that you may become the CEO of your financial life. By understanding the financial world and how it is designed, you will understand how to make informed financial decisions. (See page 35)
David Mandler – Partner, Quattro Advisors

5:30 – 6:30 p.m.
RESIDENTS RECEPTION

7:00 – 10:00 p.m.
FUN NIGHT AT TABLE ROCK CENTRE
Elements on the Falls Restaurant & Grand Hall
Scientific Program

SATURDAY, SEPTEMBER 15, 2012

7:30 – 8:30 a.m.
ANNUAL BUSINESS MEETING

7:30 – 8:30 a.m.
RESIDENTS BREAKFAST
Resident Roundtable with Young Urologists
An interactive session giving residents the opportunity to discuss issues regarding the transition to practice with Young Urologists from both Canada and the USA. The panel will include Urologists from both academic and community practice.
Raj Goel, Nick Power, Elise De, Elan Salzhauer

8:30 – 8:45 a.m.
BEST-OF-POSTERS
Presented by moderators of Friday’s poster sessions

8:45 – 9:00 a.m.
AUA GUIDELINES PANEL UPDATE
Hassan Razvi

9:00 – 9:45 a.m.
PLENARY VII
Image-guided Robotic Urologic Surgery
With advances in medical imaging, biomedical engineering and computer science, inroads have been made to enhance preoperative planning and ultimately intraoperative surgical navigation by providing accurate anatomical relationships between critical structures to be displayed during surgery. This presentation will highlight the current preclinical studies regarding image-guided robotic urologic surgery and will address the challenges associated with radical prostatectomy and partial nephrectomy.
Li-Ming Su – University of Florida

9:45 – 10:00 a.m.
BREAK

10:00 – 10:45 a.m.
Panel
Laparoscopy Video: How I Do It...
Anil Kapoor, Patrick Luke, Khurshid Guru, Jean Joseph
Moderator: Li-Ming Su

10:45 – 11:30 a.m.
AUA COURSE OF CHOICE
Management of Non Muscle Invasive Bladder Cancer: Practical Solutions for Common Problems
This presentation will examine challenging yet common problems encountered when managing patients with non-muscle invasive (Ta/T1) bladder cancer. Specifically, the current use of urinary markers in this population as well as management of the patient with a persistently positive cytology will be addressed.
Cheryl T. Lee – University of Michigan

11:30 a.m.– 12:15 p.m.
NEW RESIDENT REACH FOR THE TOP COMPETITION
Reach For The Top was a Canadian quiz show in the 1970s for bright students. This year’s NS-AUA Reach For the Top competition will see a revisiting of the War of 1812... USA vs. Canada. The brightest residents from the USA and Canada will challenge for the championship! Their urology knowledge will be tested by two excellent quiz masters, Drs. Anil Kapoor and Tim Averch. This will be an event you won’t want to miss!

12:15 p.m.
ADJOURN

SATURDAY AFTERNOON OPTIONS

Noon – 5:30 p.m.
GOLF TOURNAMENT
Thundering Waters Golf Club

12:30 – 4:30 p.m.
VOLUNTEER OPPORTUNITY
Red Roof Retreat

1:00 – 5:00 p.m.
TOUR OPTION
Art of the Blend

6:30 – 10:00 p.m.
PRESIDENT’S RECEPTION & BANQUET
Needs Assessment

Urologic diseases account for a high proportion of health care resources. Physicians providing care for patients with urologic conditions seek the highest standards of patient care and safety. Each year there are advancements in patient care and technology, which in turn require knowledge transfer amongst care givers. A variety of educational opportunities currently exist for urologists and the NS AUA annual meeting and scientific program is an excellent forum for fulfilling the needs of our membership. We have endeavored to create a diverse program with a number of different formats (Plenary lectures, Expert and Video Panels, Resident debates, and Poster sessions) to provide state-of-the-art information. We have based our program on the needs assessments provided by attendees at the 2011 meeting, as well as review of the programs of other major societies’ meetings. The AUA guidelines have also provided a framework for the choice of subjects to be presented at the meeting.

The results of the 2005 and 2010 AUA Annual Meeting attendee surveys revealed that a revolution is occurring in medicine with the rapidly expanding use of minimally invasive surgical techniques, including laparoscopy and robotics. The application of MIS techniques within our specialty has created knowledge and practice gaps for many urologists. The 2012 Section meeting will feature a Plenary lecture addressing the application of image-guidance and computer technologies in the field of urologic MIS surgery. Immediately following this Plenary will be a video panel including many internationally recognized experts demonstrating surgical techniques and troubleshooting during difficult procedures. This panel will facilitate interactive discussion help overcome the gaps identified by participants.

In 2012, Renal Cell Carcinoma (RCC) remains the deadliest urologic malignancy. The spectrum of disease, from the small renal mass to the management of advanced/aggressive RCC, is a common problem for urologists. Within the last decade there has been rapid changes in the management of patients all along this spectrum. AUA members have identified the management of RCC as an important area of knowledge and practice gaps as evidenced by the number of sessions addressing these issues at both the sectional and main AUA meetings. The 2012 NS AUA meeting will host a leader in the field discussion the management of aggressive RCC and thereafter, a panel discussion with experts will review management cases for small renal tumors. Thus, the full spectrum of RCC will be addressed.

Genitourinary reconstruction and trauma is a field within our specialty that receives limited attention at many meetings. Much of the work published in this field is level 4 evidence. We have assembled an expert panel of speakers to use cases and evidence-based medicine in their session. The goal is change how practicing urologists handle GU reconstruction in day-to-day practice.

The management of prostate cancer is a major challenge to most urologists. This is the most common malignancies in males and remains a large burden of disease in our society. Increasingly, accountability for prostate cancer care is entering the public domain. One such initiative involves Cancer Care Ontario, the provincial cancer agency for the province of Ontario. One Plenary session will detail this initiative and the improvements in the quality of care that have resulted. We anticipate that this session will improve knowledge and practice gaps with respect to radical prostatectomy and prostate cancer care.

Additionally, we are pleased to have a world-renowned nonurologist Plenary speaker who is a thought-leader in Evidence-based Medicine with particular interest in surgery. In this session, the speaker will outline major accomplishments in the realm of evidence-based medicine and its’ application to surgery. Within surgical specialties such as urology, the application of clinical trials and guidelines is continually evolving. This is an area of particular interest to urologists practicing in both academic and community settings.

The Scientific Program for 2012 provides diverse learning formats including plenary lectures, expert panel discussions and poster sessions presented by many of AUA’s experts. These different formats will allow attendees opportunities to improve their knowledge gaps and potentially change their practice patterns. The meeting offers a maximum of 16.25 AMA PRA Category 1 Credit(s)™.

LEARNING OBJECTIVES

AT THE CONCLUSION OF THE 2012 ANNUAL MEETING, PARTICIPANTS SHOULD BE ABLE TO:

- Discuss the application of the AUA, CUA, and NCCN guidelines in respective practices
- Describe recent developments in the medical and surgical management of patients with urologic malignancies, endourologic stone management, female incontinence and pediatric urology
- Describe minimally invasive techniques for urologic diseases and their risks and benefits
- Evaluate results of various laparoscopic and robotic approaches and techniques for benign and malignant urologic diseases
- Analyze diagnostic approaches and potential treatments in pediatric urologic practice and specify possible solutions
- Develop an approach to the application of evidence-based medicine within surgery and specifically urology
- Construct current management options for patients with simple and complex urinary tract stone disease
- Develop an awareness of surgical quality of assurance measures and new initiatives including the Cancer Care Ontario guidelines for radical prostatectomy
Social Program

EXHIBIT HALL GRAND OPENING RECEPTION
THURSDAY, SEPTEMBER 13, 2012
Time: 6:00 – 7:00 p.m.
Cost: Free
Step back 200 years for the anniversary of the War of 1812 as costumed soldiers welcome you to the official opening of the Exhibit Hall! Please be sure to visit the exhibitors on the floor to thank them for supporting the NS-UAUA Annual Meeting. We couldn’t do it without their support!

TOURS
The following tours have been reserved for guests on Thursday, September 13; Friday, September 14; and Saturday, September 15, 2012. Each tour group will meet in the lobby of the Marriott Gateway on the Falls Hotel prior to departure. Guests are encouraged to pre-register for tours when they pre-register for the conference, as tours will fill quickly. On-site tour registration will take place on Wednesday, September 12 from 5:00 – 7:00 p.m. and on Thursday, September 13 between 7:00 a.m. – 5:00 p.m. and will be available on a first-come, first-served basis. Payments can be made on site at Registration for any tours that have not been pre-registered or pre-paid.

Please note that if minimum numbers are not met, tours will be cancelled. For this reason we recommend that you pre-register for tours that you plan to attend.

SPOUSE TOUR OPTIONS

SHAW FESTIVAL
THURSDAY, SEPTEMBER 13, 2012, 1:00 – 5:00 P.M.
Cost: $135 – includes your premium seat at the Festival Theatre, transportation, driver gratuities, and all applicable taxes.

Join this tour and travel to the quaint town of Niagara-on-the-Lake to enjoy the wit and repartee of Noël Coward in his bold play, Present Laughter.

Noël Coward was one of the world’s first celebrities and this play is both a celebration and a comic expose of what it’s really like to be a famous and beloved man. He wrote this play in 1939 as an affectionate send-up of himself (with surprisingly honest insights) and played it on tour in 1942 and subsequently in London and America. The central role of the beloved Garry Essendine has since attracted numerous leading men in a series of suave dressing gowns including Clifton Webb, George C. Scott, Frank Langella and most recently Victor Garber. This play is full of the classic Coward wit and charm as it whisk us back to a more innocent past, when being a famous actor could still be negotiated with grace and style and even the stalkers of the stars were well-bred, well-spoken and well-dressed.

About Present Laughter: Dressing gowns, love affairs and witty repartee – glittering stage star Garry Essendine’s life is full of them all. He’s also got more visitors – and more admirers – than he knows what to do with. How can he stop a smithing ingénue, an intense young playwright and a married seductress, from declaring their admiration? And as his not-Quite-ex wife reminds him, he’s getting a bit old for all of these romantic games. Can he escape from his fans in time? And does he want to?

NIAGARA HIGHLIGHTS TOUR
FRIDAY, SEPTEMBER 14, 2012
Time: 10:00 a.m. – 3:00 p.m.
Cost: $85 – includes entrance admissions, tour guide, transportation, guide and driver gratuities and all applicable taxes.
Attire: Casual clothes, comfortable walking shoes, light jacket

Water, water everywhere and not a drop to drink!
The Niagara highlights tour features that which makes Niagara Falls famous. It’s an exploration of the natural beauty and wildness and the insatiable desire by so many to conquer Mother Nature—some won, some lost—but they all left a legacy of great stories. A seasoned local tour professional will oversee your tour—combining charm, humor and knowledge. Tour highlights include the Maid of the Mist, the White WaterWalk and the Niagara Gorge.

Water rushes all around as you “soak” in the excitement and explore the roar of the Falls. A historical ride aboard the world-famous Maid of the Mist is a half hour thrill of a lifetime! North America’s oldest tourist attraction, millions of visitors have enjoyed the boat tours since 1846. A recyclable souvenir raincoat is provided to help keep you dry from the mist and spray.

On the White WaterWalk, at the edge of one of the world’s wildest stretches of whitewater, take a walk like no other. Marvel at the relentless power and beauty of nature and see how the deep and narrow Great Gorge was created. Trillions of gallons of water are forced into this accelerating trough—the sight will take your breath away!

Please note that time will be provided for a lunch break. The cost of lunch is not included in the tour, but your guide will direct you to an area with several restaurant choices.

TOUR OPTION
ART OF THE BLEND
SATURDAY, SEPTEMBER 15, 2012
Time: 1:00 – 5:00 p.m.
Cost: $130 – includes three hour wine session, transportation, driver gratuities, and all applicable taxes.

Hillebrand has been crafting fine VQA wines from premium grapes grown in the four appellations of Niagara-on-the-Lake for more than 30 years. Nestled between the Niagara escarpment and Lake Ontario, they
Social Program

have made their home in a wine growing region that provides the diversity to grow a number of varietals in unique growing conditions. A visit to Hillebrand is an unrushed sensory experience, a time out that lets you taste, feel and discover.

The Art of the Blend Experience has been rated the #1 group activity in Niagara. It is a unique team-building experience that allows you to participate in an interactive, hands-on blending experiment. A wine consultant will lead the experience and provide participants with insight on the characteristics of the grape varieties which are assembled to create Trius Red. You will participate in blending teams and be asked to create your own unique blend. Teams will name and bottle their own blends and you will each take home a bottle with a customized label as a memory of the experience. The final blends will be judged by a wine consultant and the winning team will receive special recognition.

5K FUN RUN/WALK
FRIDAY, SEPTEMBER 14, 2012
Time: 6:30 – 8:00 a.m.
Cost: $25 – includes t-shirt, race director, water, sports drinks and snacks.

For runners and walkers, come and run or walk! If you prefer, be a sleepwalker – stay in bed and contribute to the Section’s Foundation in support of educational and research grants for residents.

Join your colleagues for an early morning Fun Run around Niagara Falls. The route will include running along the Niagara Parkway, what Winston Churchill once described as “the prettiest Sunday afternoon drive in the world” and then passing the Falls.

You can pre-register for this event when you pre-register for the conference or you can register on-site. Prizes will be given to the top 3 male and female participants. Race begins at 7 a.m.

GOLF TOURNAMENT
THUNDERING WATERS GOLF CLUB
SATURDAY, SEPTEMBER 15, 2012
Time: Noon – 5:30 p.m.
Cost: $150 - includes 18 holes of golf with personalized shared electric golf cart with GPS system, access to the warm-up area with range balls, bag valet and club cleaning service, welcome package, full use of locker room facilities, transportation to/from Thundering Waters, driver gratuities, non-alcoholic beverages, and snacks.

Thundering Waters is John Daly’s first “Signature” golf course in Canada. The golf course features the high risk-reward style of John Daly to enhance the excitement for players of all skill levels. Thundering Waters combines the parkland tranquility of Augusta National and the wind swept dunes of heathlands British Open Championship golf. Sweeping fairways, undulating greens, sculpted bunkers and meandering creeks, all nestled between towering trees and mighty dunes combine to create a true masterpiece.

Transportation will depart the hotel immediately following Saturday’s Plenary session. Tee times will begin promptly at 12:30 p.m. to allow enough time for 18 holes of golf.

Players are invited to bring their own clubs or to rent from Thundering Waters. Club rentals are available for $40 per set, plus taxes. Club rentals are not included in the cost and are your responsibility, and arrangements must be made no later than September 5, 2012. Softspike golf shoes are recommended, but you can also play with non-spikied athletic/running shoes.

Note: For those players bringing their own golf clubs, your clubs will be transported to the golf course on Saturday, September 15. As such, all golf clubs must be tagged with your name when they are dropped off. Please drop off your clubs by 8 a.m. on Saturday morning.

FUN NIGHT AT
TABLE ROCK CENTRE
ELEMENTS ON THE FALLS RESTAURANT & GRAND HALL
FRIDAY, SEPTEMBER 14, 2012
Time: 7:00 – 10:00 p.m.
Cost: If you have registered for the NS-AUA’s 2012 Annual Meeting, you will receive one complimentary ticket for Fun Night; additional tickets can be purchased for $100 for adults; children ages 4-12 are $50; children 3 years and under are free. (Please be sure to list the total number of tickets you will need, including yourself, on the registration form.)

Table Rock Welcome Centre is the heart of Niagara Parks – where every year over 8 million visitors stand close to the thundering water rushing over the brink of the Horseshoe Falls! Hundreds of years ago, the land on which the pedestrian walkway at the brink of the falls and Table Rock now stands, formed part of the Falls and was covered with fast flowing water.

Today, take a journey deep below and behind the heart of Niagara and stand in the mist where the mighty Horseshoe Falls tumbles from 13 stories above! The sound is like thunder, the sight awe-inspiring. At Journey Behind the Falls, you will experience the awesome spectacle of one-fifth of the world’s fresh water crashing down to the basin below.

Don’t miss Niagara’s newest attraction – Niagara’s Fury. The temperature will drop. Water will bubble and spray while snow falls all around. Standing on a massive platform you will feel the wrath of Mother Nature as the floor tilts and trembles beneath you. This is Niagara’s Fury! Niagara Parks has recreated the amazing sights and sounds of the creation of Niagara Falls. Incredible images developed with technology used previously only in satellites and medicine will immerse you in a 4D attraction.
Fun Night at Table Rock Centre

Elements on the Falls
Restaurant & Grand Hall
Friday, September 14, 2012
7:00 – 10:00 p.m.

Enjoy dinner with local wines, feel the thunder at Journey Behind the Falls, and experience Niagara’s Fury, a 4D attraction recreating the creation of Niagara Falls.

Free with Annual Meeting Registration
Guests: $100 for adults; children ages 4-12 are $50; children 3 years and under are free.

See page 29 for details.
**Social Program**

**VOLUNTEER OPPORTUNITY**

**RED ROOF RETREAT**

**SATURDAY, SEPTEMBER 15, 2012**

- **Time:** 12:30 – 4:30 p.m.
- **Cost:** $30 – includes transportation and driver gratuities

Since 2001 Red Roof Retreat, a Niagara Region Charity, has provided quality recreational, educational and respite services to children, youth and young adults with special needs and their families. They create opportunities for relationships to develop and for skills to grow. Red Roof Retreat provides respite, recreation and education for children and young adults with a variety of special needs, including:

- Summer day camp for ages 5 to 21
- Respite services each weekend
- Day programs for young adults
- Continuing education for caregivers and professionals
- Educational school trips for all ages
- Horseback riding, teen nights, and Saturday Day Program

Red Roof Retreat has been a leader in meeting the growing requirements of special needs families in the greater Niagara area. There are currently more than 3,500 families in the Niagara Region with special needs. It costs over $3,000 per weekend to provide respite care to 5 special needs children/young adults. This assistance is costly in a region where the median household income is $53,057, according to the last Census data, and 11% of Niagara families are living in low-income households. Red Roof charges families just $130 per weekend, making it more affordable, but increasing the demand for help to continue these programs.

Red Roof Retreat is a rural-based retreat and our group will likely be working outdoors. Our exact activity will be determined at a later date, but previous groups have built a barbeque area, worked in the yard, built fencing, and done brickwork.

In New Orleans at last year’s Annual Meeting a group of volunteers generously donated their time to help the St. Bernard Project rebuild homes of Hurricane Katrina survivors. Past President Dr. James W.L. Wilson and Mrs. Jean Wilson commented that “The opportunity to help at the St. Bernard Project was a unique experience for us at a scientific meeting. It allowed us to participate in something entirely different, to see a part of the community from a perspective not normally accessible to tourists and quite different from media reports, and perhaps even to be of assistance. Oh yes, we had a lot of fun too.”

Board of Directors Representative Dr. Timothy D. Averch and Mrs. Joanne Averch rearranged their family’s schedule when they heard of the project in New Orleans, and their son, Jake Averch, missed a school dance, music rehearsal, two hockey games, and a friends’ Bar Mitzvah just to participate as a family! Mrs. Averch recognizes that “…taking the time as a family to enhance the life of someone in need is a humbling experience. There was a moment between prepping wall sockets and clearing debris from the yard, when Jake turned to me and said ‘I am glad we came’ …as a parent that is an Aha moment!”

**PRESIDENT’S RECEPTION AND BANQUET**

**SATURDAY, SEPTEMBER 15, 2012**

- **Location:** Marriott Gateway on the Falls
- **Attire:** Semi-formal attire
- **Time:** 6:30 – 10:00 p.m. (Reception at 6:30 p.m.; Banquet, Program and Awards at 7:00 p.m.)
- **Cost:** If you have registered for the NS-AUA’s 2012 Annual Meeting, you will receive one complimentary ticket (Residents receive two tickets). Additional tickets are $75 and can be purchased at the Registration Desk.

Join us for a reception and dinner with keynote speaker, Clark Bernat.

Born in St. Catharines, Clark Bernat developed a great appreciation for Museums due to his many visits to cultural institutions with his grandfather and parents. Clark has a History degree from Brock University. While working one summer at the St. Catharines Museum, he developed an appreciation for the challenges facing museums in Ontario. He continued his studies at the University of Leicester, completing a Master’s Degree in Museum Studies which included a placement at Belgrave Hall in Leicester, his dissertation entitled “Upon Further Review: Black History in Community Museums after Into the Heart of Africa”, development of the Leicester Museum Services’ children’s component of their website and participation in a Museums Association initiative to improve Cultural Diversity in Museums.

Clark has worked at Battlefield House Museum, Backus Heritage Village, the Niagara Historical Society & Museum and Chaired Doors Open Niagara and the Museums of Niagara Association. He has authored, The Friendly Invasion, co-authored Niagara-on-the-Lake and was the editor of 100 Years-100 Artefacts. He has been with the Niagara Falls Museums since September 2010, where he has overseen operations of the City’s three museums. In July 2012, the Niagara Falls History Museum will open to the public after 2 years and a $12 million expansion that was designed by Moriyama and Teshima. The expansion includes the R.D. Gale Family War of 1812 Gallery, the Community Gallery and the OPG Temporary Gallery. Clark lives in St. Catharines with his wife and two children.
President’s Reception & Banquet

Saturday, September 15, 2012
Marriott Gateway on the Falls
6:30 – 10:00 p.m.

Join us for a reception and dinner with keynote speaker, Clark Bernat.

Reception at 6:30 p.m.
Banquet, Program and Awards at 7:00 p.m.

Attire: Semi-formal

Cost: If you have registered for the NS-AUA’s 2012 Annual Meeting, you will receive one complimentary ticket (Residents receive two tickets). Additional tickets are $75 and can be purchased at the Registration Desk.

See page 31 for details.
Quick Guide to Niagara Falls

HIGHLIGHTS

Tourist Information: http://www.niagarafallstourism.com/

Once you’ve had a chance to see the Falls from the sidelines, getting up close is a must!

Falls Experiences – The Maid of the Mist takes visitors on a boat ride tour at the foot of the Falls for a view of the 13-story falls from below. A completely different sensation, Journey Behind the Falls sounds like thunder as you descend to tunnels that travel to Observation Decks literally behind the Falls. Get some fresh air at the boardwalk on the edge of the Niagara whitewaters – the White Water Walk – which includes a photo gallery of stunts and daredevils from Niagara history. Don’t forget to sign up for the NS-AUA Fun Night and Friday’s spouse tour where you can enjoy these attractions!

Old Fort Erie – Step back into a time of red coats, black powder, and gray fortress walls. Over 200 years of living history resides within at Old Fort Erie, the site of ancient flint quarries, the first fort built in Ontario by the British, Canada’s bloodiest field of battle, and the major crossing point into Canada of the Underground Railroad.

Niagara Falls History Museum – Housing a vast collection of Niagara Falls history, the museum is located within steps of the Drummond Hill Cemetery, which is the focal point for the Battle of Lundy’s Lane which was the “bloodiest battle of the War of 1812”.

Wineries – Whether you are an avid wine lover or just enjoy a beautiful country escape with a bit of food and drink, a Niagara wine tour beckons. Remarkably, the entire Niagara wine region - the peninsula along the shores of Lake Ontario – is home to over 50 wineries. Join us on Saturday for the NS-AUA tour at Hillebrand Winery for the “Art of the Blend Experience” where you will have the opportunity to work together to create your own blend of wine!

Rossi Glass – Come and be fascinated as you watch the talented artisans create beautiful works of art right before your eyes. Rossi Glass is the only manufacturer of Cranberry Collectible Glass in North America. You will find many unique pieces of Collectible Cranberry Glass, as well as many new creative art glass pieces.

Botanical Gardens – Established in 1936, you’ll enjoy 99 acres of beautifully maintained gardens. Footpaths wind past the Butterfly Conservatory and butterfly garden, ponds, and an arboretum featuring one of Canada’s finest collections of ornamental trees and shrubs.

Fishing – Niagara contains an extensive system of rivers and lakes for great sport fishing. Niagara offers guided fishing charter tours on Lake Ontario, the Niagara River, and Lake Erie.

WEATHER

The average high temperature in Niagara Falls in September is 72°F. The average low temperature is 51°F. Also, keep in mind that even on the sunniest days, visitors close to the falls can get quite wet from the mist if the wind is blowing your way.

AIRPORTS/TRANSPORTATION:

BUFFALO/NIAGARA INTERNATIONAL AIRPORT (BUF)

http://www.buffaloairport.com

Averaging approximately 110 daily flights with nonstop service to 23 airports, BUF Airport is the closest major airport to the NS-AUA Annual Meeting. We recommend this airport to all travelers from the U.S. It is located approximately 27 miles from the Marriott.

Taxis: Airport Taxi has been the only official taxi operator at the BUF Airport for over 40 years and is the largest taxicab operation in the region offering service 24 hours/day. Their taxi stand is located directly outside the Baggage Claim Area from the lower level. Approximate fare for one passenger to the Marriott is $55 one way and $85 one way for two passengers. Note that fares are subject to change. If you need a return trip to the airport or anywhere in the area, they can be reached at 716-633-8294 or 1-800-551-9369.

Airport Shuttle: Buffalo Airport Shuttle service is available
Quick Guide to Niagara Falls

from the airport to the hotel for approximately $55 (one passenger, one way) or $78 (2-4 passengers, one way). Note that fares are subject to change. For arrivals and departures, please call no later than 24 hours in advance. Call 716-685-2550 for more details or to make reservations. For more information, please visit http://www.buffaloairportshuttle.com/index.html.

Please be sure to bring proper identification with you if you are traveling from the United States to Canada. Knowing what documents are required and having them ready when you return home will help ensure your return is as smooth as possible. Starting June 2009, U.S. citizens returning home from Canada are required to present one of the following travel documents: U.S. Passport, U.S. Passport Card (limited-use travel document that fits in your wallet and costs less than a Passport, but is only valid for travel by land and sea), Enhanced Driver’s License (EDL), or Trusted Traveler Program Card. Enhanced Driver’s Licenses are available in select U.S. states, including New York, Vermont, and Michigan, and Canadian provinces. The licenses denote both identity and citizenship, and are specifically designed for cross-border travel into the U.S. by land or sea. For more information on this Western Hemisphere Travel Initiative (WHTI), please visit http://www.getyouhome.gov/html/lang_eng/eng_edl.html. We encourage you to check current travel requirements closer to your departure date with the Canada Border Services Agency at http://www.cbsa-asfc.gc.ca/security-securite/admiss-eng.html.

TORONTO PEARSON INTERNATIONAL AIRPORT (YYZ)


Toronto Pearson is Canada’s largest and busiest airport. This architecturally stunning, completely functional and incredibly friendly airport is the hub for 400,000 flights a year and nearly 32 million guests annually. YYZ Airport is located approximately 78 miles from the Marriott.

Taxis: Approximate fare to the Marriott is $186 one way. Taxis and limos are available at the Arrivals Level of each terminal.

Airport Shuttle: A number of companies offer bus and shuttle service to and from Toronto Pearson. Information counters are located on the Ground Level of Terminal 1 and on the Arrivals Level of Terminal 3. More information is available at http://www.torontopearson.com/en/toandfrom/outoftown/.

RENTAL CARS:

Hertz is pleased to offer special discounted car rental rates for the AUA 2012 NSAUA.

Call 1-800-654-2240 and mention the 2012 AUA discount code CV# 045G0001.

NORTHEASTERN SECTION FOUNDATION RESEARCH & EDUCATION FUND
DONATE TODAY
DO YOU WANT TO LEARN HOW TO TAKE CONTROL OF YOUR FINANCIAL LIFE?

THEN JOIN US FOR THE FIRST ANNUAL YOUNG UROLOGIST MENTORING PROGRAM.

Following a networking reception, invited speaker David Mandler will reveal the secret of how to obtain financial success. This presentation will educate and advise you so that you may become the CEO of your financial life. By understanding the financial world and how it is designed, you will understand how to make informed financial decisions.

FRIDAY, SEPTEMBER 14
4:30 – 6:00 P.M.
MARRIOTT HOTEL, SALON A

Admission to this event is included with annual meeting registration, and open to attendees in their first 15 years of practice.

DAVID MANDLER, PARTNER, QUATTRO ADVISORS

David Mandler graduated from The Pennsylvania State University Smeal College of Business. David has helped many families understand the significance of client service as opposed to product service. His expertise is in coordinating the client’s microeconomic financial decisions in all areas of finance focusing on their overall goals. By doing this, he is able to help families maximize the efficiency and minimize the cost associated with accomplishing these goals.

David’s practice specializes in working with medical and dental professionals. He understands that practicing medicine is not a 9-5 job and therefore the importance of being available before and after business hours for the convenience of the client. David also has an extensive understanding of the unique issues facing those in the medical and dental fields. This includes issues such as, the costs associated with many years of education, the need to implement strategies that maximize savings in a shorter period of time, and the need for the protection of their assets.
Exhibitor Directory

Abbott
200 Abbott Park Road
Abbott Park, IL 60064
847-938-7353
www.abbott.com
Abbott is a global, broad-based health care company devoted to discovering new medicines, new technologies and new ways to manage health. Our products span the continuum of care, from nutritional products to medical devices and pharmaceutical therapies. Our comprehensive product line encircles life itself – addressing important health needs for all ages.

Allergan
2525 Du Pont Drive
Irvine, CA 92612
714-246-4500
www.allergan.com
Allergan is a multi-specialty health-care company established in 1950 with a commitment to helping people reach their life’s potential. With more than 10,000 employees worldwide, we are committed to discovering new therapies to treat unmet medical needs in eye care, medical aesthetics, medical dermatology, obesity intervention, urology, and neurosciences. APC55EV12

American Medical Systems
10700 Bren Road West
Minnetonka, MN 55343
952-930-6116
www.americanmedicalsystems.com
AMS is a leading provider of world-class devices and therapies for male and female pelvic health. The company’s products were used to treat approximately 340,000 patients in 2010. AMS is a wholly owned subsidiary of Endo Pharmaceuticals, a U.S.-based, specialty healthcare solutions company, focused on high-value branded products, services and devices and specialty generics (http://www.endo.com).

Amgen
One Amgen Center Drive
Thousand Oaks, CA 91320
805-447-1000
www.amgen.com
Amgen, a biotechnology pioneer, discovers, develops, and delivers innovative human therapeutics. Our medicines help millions of patients in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease, and other serious illnesses. With a deep and broad pipeline of potential new medicines, we continue to advance science to serve patients.

Astellas Pharma
One Astellas Parkway
Northbrook, IL 60062
224-205-8800
www.astellas.us
Astellas Pharma US, Inc., located in Northbrook, Illinois, is a U.S. affiliate of Tokyo-based Astellas Pharma Inc. Astellas markets products in the areas of Anti-Infectives, Cardiology, Dermatology, Neuroscience, Oncology, Transplant, and Urology. For more information about Astellas Pharma US, Inc., please visit our website at www.astellas.us.

Astellas/Medivation
One Astellas Parkway
Northbrook, IL 60062
224-205-8800
www.astellas.us
Astellas Pharma Inc. is a pharmaceutical company dedicated to improving the health of people around the world. The organization is committed to becoming a global leader in Oncology. Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options.

AstraZeneca Canada
1004 Middlegate Road
Mississauga, Ontario L4Y 1M4
800-565-5877
AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialization of prescription medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit the company’s website at www.astrazeneca.ca.

biolitec, Inc.
515 Shaker Road
East Longmeadow, MA 01028
203-979-2737
www.biolitec-usa.com
biolitec® introduces the EVOLVE® Dual Laser and Twister™ fibers. The combination of this compact but effective dual wavelength laser in combination with the Twister™ fiber can vaporize and remove the obstructing prostate tissue that causes the symptoms of BPH. Eliminating the obstruction and causing virtually no damage to surrounding tissue.
Exhibitor Directory

Boston Scientific
100 Boston Scientific Way
Marlborough, MA 01752
508-650-8000
www.bostonscientific.com

Boston Scientific is a leading developer of less-invasive medical technologies. Products include devices for the diagnosis and treatment of kidney stones, female urinary incontinence, pelvic floor reconstruction, and BPH. Please visit our exhibit to learn about our newest technologies, full line of products, and our commitment to physician education.

Calmoseptine Inc.
16602 Burke Lane
Huntington Beach, CA 92647
714-840-3405
www.calmoseptine.com

Calmoseptine Inc. promotes Calmoseptine Ointment for the prevention and treatment of skin irritations from moisture such as urinary and fecal incontinence. It is also effective for irritations from perspiration, wound drainage, fecal & vaginal fistulas and feeding tube site leakage. Calmoseptine Ointment temporarily relieves discomfort and itching. Free samples at our booth!

Coloplast Corporation
1601 West River Road
Minneapolis, MN 55411
800-258-3476
www.us.coloplast.com

Making life easier for people with intimate healthcare needs, Coloplast produces a range of surgical devices to help people who suffer from urological conditions such as urinary incontinence, pelvic organ prolapse and erectile dysfunction. Coloplast’s latest innovation is the new Titan Zero Degree Penile Prosthesis.

Cook Medical
P.O. Box 489
Bloomington, IN 47402
800-468-1379
www.cookmedical.com

Cook Medical has been a leading supplier of medical devices for urologists for over 35 years—offering interventional and bio-designed technologies that support diagnostic and therapeutic procedures in adult and pediatric urology; with an emphasis in stone management and male and female pelvic health. Pioneering urological products for a physician to use and a patient to trust.

Dendreon Corporation
1301 Second Avenue, Suite 3200
Seattle, WA 98101
www.dendreon.com

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response.

Domier MedTech America, Inc.
1155 Roberts Blvd., N.W.
Kennesaw, GA 30144
www.domier.com

Domier MedTech develops, manufactures, markets and services lithotripters, orthopedic shock wave devices, urotubulars and medical aesthetic lasers worldwide, providing innovative therapeutic, diagnostic and service solutions for numerous healthcare fields. As the pioneer of extracorporeal shockwave lithotripsy (ESWL), Domier continues to revolutionize the urology market with distinctive lithotripters and urology imaging tables, including the Compact Sigma, Compact Delta and Opus II.

Eli Lilly Canada
3650 Danforth Avenue
Toronto, ON M2N 2E8
519-280-3083
www.Lilly.ca

Lilly is a leading, innovation-driven Pharmaceutical Corporation committed to developing a growing portfolio of best-in-class pharmaceutical products that help people live longer, healthier and more active lives. We are committed to providing answers that matter through medicines and information, for some of the world’s most urgent medical needs.

Ferring Pharmaceuticals
4 Gatehall Drive, 3rd Floor
 Parsippany, NJ 07054
973-610-6070
www.ferring.com

Ferring Pharmaceuticals B.V. markets FIRMAGON® (degarelix for injection) for advanced prostate cancer. Ferring Pharmaceuticals B.V. focuses on marketing innovative products in the fields of urology, infertility, obstetrics, gastroenterology, endocrinology, and osteoarthritis. Contact us at 1-888-FERRING (337-7464), 1-855-UROSERVICES (876-7378) or stop by our booth for more information.
Exhibitor Directory

**HealthTronics**
9825 Spectrum Dr., Bldg. 3
Austin, TX 78717
888-252-6575
www.healthtronics.com

HealthTronics has been a leading provider of comprehensive, integrated urological products, services and solutions for urologists, hospitals, surgery centers and clinics across the U.S. for over 20 years. Our solutions include lithotripsy, laser therapy, cryotherapy, percutaneous image guided cryoablation, uropathology and electronic medical records.

**Intuitive Surgical**
1266 Kifer Road
Sunnyvale, CA 94086
408-523-2100
www.intuitivesurgical.com

Intuitive Surgical, maker of the da Vinci® Surgical System, is the global leader in robotic-assisted, minimally invasive surgery. da Vinci enables surgeons to offer a minimally invasive approach to patients facing prostate, bladder or kidney cancer, as well as kidney disorders. da Vinci is chosen by more U.S. men than any other prostate cancer treatment.

**Janssen Inc.**
19 Green Belt Drive
Toronto, Ontario M3C 1L9
www.janssen.ca

As a member of the Janssen Pharmaceutical Companies of Johnson & Johnson, Janssen Inc. is dedicated to addressing and solving the most important unmet medical needs of our time. Driven by our commitment to the passionate pursuit of science for the benefit of patients, we work together to bring innovative ideas, products and services to patients across Canada and around the world.

**KARL STORZ Endoscopy-America**
2151 E. Grand Avenue
El Segundo, CA 90245
800-421-0837
www.karlstorz.com

KARL STORZ offers solutions for minimally invasive adult and pediatric urology, endourology and laparoscopic urologic procedures. We strive to advance endoscopic technology, including digital flexible endoscopes to enhance improved imaging, and photodynamic diagnosis (PDD) for cystoscopic tissue characterization in patients with known or suspected non-muscle-invasive papillary cancer of the bladder.

**KARL STORZ Lithotripsy-America**
1000 Cobb Place Blvd., Bldg. 400, Suite 450
Kennesaw, GA 30144
800-965-4846
www.karlstorzlitho.com

The Storz MODULITH® SLX-F2 is a one-of-a-kind lithotripter as well as a diagnostic and therapeutic workstation. Equipped with patented, electromagnetic shock wave technology, offering selectable focus as well as in-line ultrasound and x-ray localization capabilities, the F2 provides unparalleled reliability and precision in treatment. With more than 700 various systems operating worldwide, Karl Storz Lithotripsy - America, Inc. provides nationwide sales and customer support, service technicians and applications training, plus financing and leasing options.

**Laborie Medical Technologies**
6415 Northwest Drive, Unit 10
Mississauga ON L4V 1X1
888-522-6743
www.laborie.com

LABORIE, the worldwide industry leader in Urodynamics, is pleased to provide you with the most advanced solutions in Pelvic Floor Dysfunction Management. LABORIE is committed to bringing you the most innovative products; from private offices to world class research institutions, our solutions are designed to expand with your practice.

**Meda Pharmaceuticals**
265 Davidson Ave
Somerset, NJ 08873
781-472-0477
www.medapharma.us

Meda Pharmaceuticals Inc. is the U.S. subsidiary of Meda AB. The Meda Pharmaceutical product portfolio is focused primarily on respiratory, allergy, central nervous system, gastroenterology, musculoskeletal, rheumatology, erectile dysfunction, and women's health products.

**Medispec Ltd.**
20410 Observation Drive, Suite 102
Germantown, MD 20876
888-663-3477
us.medispec.com

Medispec is a leading designer and manufacturer of affordable shock wave lithotripsy systems for the worldwide medical community. The E300 ESWL system combines a large focal zone with a high bar pressure, making it one of the most effective lithotripters currently available. Alongside is our electromagnetic lithotripter offering a quieter operation.
Exhibitor Directory

Miraca Life Sciences 411
6655 N. MacArthur Blvd.
Irving, TX 75039
214-596-2229
www.miracalifesciences.com

Serving more than 3,000 patients each day, Miraca Life Sciences is a leader in providing academic-caliber pathology services in the fields of dermatopathology, GI pathology, hematopathology and urologic pathology. We employ a talented team of leading pathologists, histologists, molecular pathology experts, lab technicians and other medical professionals. (Formerly Caris Diagnostics)

Myriad Genetic Laboratories, Inc. 208
320 WakaraWay
Salt Lake City, UT 84108
www.prolaristest.com

Prolaris was developed to aid in predicting disease aggressiveness in conjunction with clinical parameters such as Gleason score and PSA. Prolaris measures the expression level of genes involved with cell cycle progression. Prolaris provides unique information about prognosis and may be used to determine appropriate therapy for prostate cancer patients.

PendoPharm, Division of Pharmascience 404
6111 Royalmount Avenue
Montreal, QC H4P2T4
514-340-9800
www.pendopharm.com

A Strong Focus on Specialty Medicines PENDOPHARM is a rapidly growing and independent business that focuses on commercializing a portfolio of specialty prescription products and an established line of OTC/BTC products. Strategically committed to growth, PENDOPHARM is actively engaged in licensing, developing and marketing late-stage prescription products as well as consumer brands.

Richard Wolf Medical Instruments 407
353 Corporate Woods Parkway
Vernon Hills, IL 60061

T-DOC Company, LLC 305
181 Edgemoor Road
Wilmington, DE 19809
US: 866-836-2552 Intl: 1+302-691-2727
www.tdocllc.com

Accurate and reliable yet simple and precise technology from the trusted people at T-DOC. Explore the innovative family of products for Pelvic Health including T-DOC Air-Charged Catheters for Urodynamics and Anorectal Manometry, plus our new line, URway pelvic floor muscle rehabilitation sensors. Visit T-DOC at booth 305 for more information.

Uroplasty Inc. 406
5420 Feltl Road
Minnetonka, MN 55343
952-426-6140
www.uroplasty.com

Uroplasty provides innovative, office-based solutions for incontinence. Macroplastique® is a predictable, permanent, proven urethral bulking agent with nearly 20 years of experience. Urgent® PC provides simple, office-based neuromodulation for Overactive Bladder. Outside the U.S. it is also used for fecal incontinence. It is proven to provide patient response of up to 80%.

Varian Medical Systems 113
3100 Hansen Way
Palo Alto, CA 94304
www.varian.com

Varian Medical Systems is the world’s leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, proton therapy, and brachytherapy. The company also supplies informatics software for managing comprehensive cancer clinics, radiotherapy centers and medical oncology practices.

Watson Pharma Inc. 306
400 Interpace Parkway, Bldg. A
Parsippany, NJ 07054
862-261-7000
www.watson.com

Watson Pharmaceuticals has a clear objective to expand our presence in Women’s Health through internal research and development and alliances that will expand our brand offerings in pre-term birth, infertility, emergency and oral contraception. Watson, a long-standing and committed partner to women throughout their reproductive lives – and beyond.
Which Side of the Border Will Win?

CANADA OR USA

Floor Plan

<table>
<thead>
<tr>
<th>EXHIBITOR</th>
<th>BOOTH #</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abbott</td>
<td>201</td>
</tr>
<tr>
<td>Allergan</td>
<td>300</td>
</tr>
<tr>
<td>American Medical Systems</td>
<td>402</td>
</tr>
<tr>
<td>Amgen</td>
<td>304</td>
</tr>
<tr>
<td>Astellas Pharma</td>
<td>103</td>
</tr>
<tr>
<td>Astellas/Medivation</td>
<td>101</td>
</tr>
<tr>
<td>AstraZeneca Canada</td>
<td>212</td>
</tr>
<tr>
<td>biolitec, Inc.</td>
<td>105</td>
</tr>
<tr>
<td>Boston Scientific</td>
<td>307</td>
</tr>
<tr>
<td>Calmoseptine Inc.</td>
<td>206</td>
</tr>
<tr>
<td>Coloplast Corporation</td>
<td>204</td>
</tr>
<tr>
<td>Cook Medical</td>
<td>312</td>
</tr>
<tr>
<td>Dendreon Corporation</td>
<td>200</td>
</tr>
<tr>
<td>Dornier MedTech America, Inc.</td>
<td>303</td>
</tr>
<tr>
<td>Eli Lilly Canada</td>
<td>202</td>
</tr>
<tr>
<td>Ferring Pharmaceuticals</td>
<td>409</td>
</tr>
<tr>
<td>HealthTronics</td>
<td>405</td>
</tr>
<tr>
<td>Intuitive Surgical</td>
<td>112</td>
</tr>
<tr>
<td>Janssen Inc.</td>
<td>210</td>
</tr>
<tr>
<td>KARL STORZ Endoscopy-America</td>
<td>310</td>
</tr>
<tr>
<td>KARL STORZ Lithotripsy-America</td>
<td>310</td>
</tr>
<tr>
<td>Laborie Medical Technologies</td>
<td>111</td>
</tr>
<tr>
<td>Meda Pharmaceuticals</td>
<td>205</td>
</tr>
<tr>
<td>Medispec Ltd.</td>
<td>203</td>
</tr>
<tr>
<td>Miraca Life Sciences</td>
<td>411</td>
</tr>
<tr>
<td>Myriad Genetic Laboratories</td>
<td>208</td>
</tr>
<tr>
<td>Pendopharm, Division of Pharmacience</td>
<td>404</td>
</tr>
<tr>
<td>Richard Wolf Medical Instruments</td>
<td>407</td>
</tr>
<tr>
<td>T-DOC Company, LLC</td>
<td>305</td>
</tr>
<tr>
<td>Uroplasty Inc.</td>
<td>406</td>
</tr>
<tr>
<td>Varian Medical Systems</td>
<td>113</td>
</tr>
<tr>
<td>Watson Pharma Inc.</td>
<td>306</td>
</tr>
</tbody>
</table>

Exhibitor List as of 8/16/12
Exhibit Hall
Continuing Medical Education

TO CLAIM YOUR CME CREDITS,
GO TO www.NSAUA.org.

Accreditation: The American Urological Association Education & Research, Inc. (AUAER) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The AUAER takes responsibility for the content, quality, and scientific integrity of this CME activity.

Credit Designation: The American Urological Association Education & Research, Inc. designates this live activity for a maximum of 16.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AUAER DISCLOSURE POLICY

As a provider accredited by the ACCME, the AUAER must ensure balance, independence, objectivity and scientific rigor in all its activities.

All persons in a position to control the content of an educational activity (i.e., activity planners and presenters) provided by the AUAER are required to disclose to the provider any relevant financial relationships they have with any commercial interest. The AUAER must determine if an individual’s financial relationships may influence the educational content with regard to exposition or conclusion, and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from serving as planners or presenters, but rather to provide the audience with information on which they can make informed judgments about the material presented.

RESOLUTION OF IDENTIFIED CONFLICT OF INTEREST

All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:

- Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or Education Content Review Committee or its subgroup.
- Limit content to evidence with no recommendations.
- Introduction of a debate format with an unbiased moderator (point-counterpoint).
- Inclusion of moderated panel discussion.
- Publication of a parallel or rebuttal article for an article that is felt to be biased.
- Limit equipment representatives to providing logistics and operational support only in procedural demonstrations.
- Divestiture of the relationship by faculty.

Off-label or Unapproved Use of Drugs or Devices: It is the policy of the AUAER to require the disclosure of all references to off-label or unapproved uses of drugs or devices prior to the presentation of educational content. The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.

Disclaimer: The opinions and recommendations expressed by faculty, authors, and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUAER.

Evidence Based Content: As a provider of continuing medical education accredited by the ACCME, it is the policy of the AUAER to review and certify that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

To Claim Your CME Credits, go to www.NSAUA.org.
65th NSAUA ANNUAL MEETING


Research, Racing, Relaxation: A WINNING TRIFECTA!